[{"title01":"Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European leukemia net risk classification","title02":"Secondary-type mutations do not impact outcome in <i>NPM1<\/i>-mutated acute myeloid leukemia - implications for the European leukemia net risk classification","journal":"Leukemia","issue":"2023 Sep 7. doi: 10.1038\/s41375-023-02016-6. Online ahead of print.","author":"Eckardt JN, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, Sauer T, Scholl S, Hochhaus A, Crysandt M, Br\u00fcmmendorf TH, Krug U, W\u00f6rmann B, Hiddemann W, G\u00f6rlich D, Sauerland C, Steffen B, Einsele H, Neubauer A, Burchert A, Sch\u00e4fer-Eckart K, Berdel WE, Schliemann C, Krause SW, H\u00e4nel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Ruhnke L, Schetelig J, Middeke JM, Serve H, Baldus CD, Platzbecker U, M\u00fcller-Tidow C, Bornh\u00e4user M, Herold T, Thiede C, R\u00f6llig C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37679502"},{"title01":"FBXO21 mediated degradation of p85\u03b1 regulates proliferation and survival of acute myeloid leukemia","title02":"FBXO21 mediated degradation of p85\u03b1 regulates proliferation and survival of acute myeloid leukemia","journal":"Leukemia","issue":"2023 Sep 9. doi: 10.1038\/s41375-023-02020-w. Online ahead of print.","author":"Dobish KK, Wittorf KJ, Swenson SA, Bean DC, Gavile CM, Woods NT, Ghosal G, Hyde RK, Buckley SM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37689825"},{"title01":"Revisiting six established practices in the treatment of chronic myeloid leukaemia","title02":"Revisiting six established practices in the treatment of chronic myeloid leukaemia","journal":"Lancet Haematol","issue":"2023 Aug 28:S2352-3026(23)00164-3. doi: 10.1016\/S2352-3026(23)00164-3. Online ahead of print.","author":"Kantarjian HM, Welch MA, Jabbour E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37652074"},{"title01":"Understanding the barriers to AML care in India","title02":"Understanding the barriers to AML care in India","journal":"Lancet Haematol","issue":"2023 Sep;10(9):e710-e711.","author":"Senapati J, Panda T, Rajendra A, Aggarwal M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37652600"},{"title01":"Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results","title02":"Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results","journal":"J Clin Oncol","issue":"2023 Sep 13:JCO2202604. doi: 10.1200\/JCO.22.02604. Online ahead of print.","author":"Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, Mannis G, Chai-Ho W, Tanaka TN, Bradley TJ, Jeyakumar D, Wang ES, Sweet K, Kantarjian HM, Garcia-Manero G, Komrokji R, Xing G, Ramsingh G, Renard C, Zeidner JF, Sallman DA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37703506"},{"title01":"Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant","title02":"Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant","journal":"Haematologica","issue":"2023 Sep 14. doi: 10.3324\/haematol.2023.283740. Online ahead of print.","author":"Begna KH, Abdallah NH, Janania-Martinez M, Mangaonkar AA, Rangan A, Herrick JL, Gangat N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37706335"},{"title01":"Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia","title02":"Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia","journal":"Haematologica","issue":"2023 Sep 14. doi: 10.3324\/haematol.2023.283800. Online ahead of print.","author":"Behrens YL, Gaschler L, Nienhold R, Reinkens T, Schirmer E, Kn\u00f6\u00df S, Strasser R, Sembill S, Wotschofsky Z, Suttorp M, Krumbholz M, Schlegelberger B, Metzler M, G\u00f6hring G, Karow A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37706343"},{"title01":"Prognostic value of European Leukemia Net 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia","title02":"Prognostic value of European Leukemia Net 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia","journal":"Haematologica","issue":"2023 Sep 14. doi: 10.3324\/haematol.2023.283606. Online ahead of print.","author":"Park S, Kim TY, Cho BS, Kwag D, Lee JM, Kim M, Kim Y, Koo J, Raman A, Kim TK, Kim HJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37706344"},{"title01":"Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies","title02":"Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies","journal":"Haematologica","issue":"2023 Sep 14. doi: 10.3324\/haematol.2023.283372. Online ahead of print.","author":"Woolston DW, Lee ND, Shadman M, Latorre-Esteves E, Tee XR, Fredrickson J, Kohrn BF, Ujjani C, Eckel A, Till B, Fang M, Radich J, Bozic I, Risques RA, Yeung CCS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37706363"},{"title01":"Maximal benefit of minimal residual disease monitoring in pediatric acute myeloid leukemia","title02":"Maximal benefit of minimal residual disease monitoring in pediatric acute myeloid leukemia","journal":"Haematologica","issue":"2023 Sep 7. doi: 10.3324\/haematol.2023.283765. Online ahead of print.","author":"Hasle H, Juul-Dam KL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37675508"},{"title01":"Frequent, high density expression of surface CD38 as a potential therapeutic target in adult T-lineage acute lymphoblastic leukemia","title02":"Frequent, high density expression of surface CD38 as a potential therapeutic target in adult T-lineage acute lymphoblastic leukemia","journal":"Haematologica","issue":"2023 Sep 7. doi: 10.3324\/haematol.2023.283814. Online ahead of print.","author":"Koslowski S, Glauben R, Habringer S, Burmeister T, Keller U, Br\u00fcggemann M, G\u00f6kbuget N, Schwartz S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37675513"},{"title01":"Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients","title02":"Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients","journal":"Br J Haematol","issue":"2023 Sep 10. doi: 10.1111\/bjh.19096. Online ahead of print.","author":"Donnette M, Hamimed M, Ciccolini J, Sicard G, Correard F, Farnault L, Ouafik L, Venton G, Fanciullino R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37691342"},{"title01":"Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia","title02":"Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia","journal":"Br J Haematol","issue":"2023 Sep 11. doi: 10.1111\/bjh.19045. Online ahead of print.","author":"Booth E, Backx M, Joshi A, Nizami H, Elmusharaf N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37696766"},{"title01":"Long-term follow-up of haploidentical haematopoietic stem cell transplantation in paediatric patients with high-risk acute myeloid leukaemia: Report from a single centre","title02":"Long-term follow-up of haploidentical haematopoietic stem cell transplantation in paediatric patients with high-risk acute myeloid leukaemia: Report from a single centre","journal":"Br J Haematol","issue":"2023 Sep 2. doi: 10.1111\/bjh.19086. Online ahead of print.","author":"Bai L, Zhang ZX, Hu GH, Cheng YF, Suo P, Wang Y, Yan CH, Sun YQ, Chen YH, Chen H, Liu KY, Xu LP, Huang XJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37658699"},{"title01":"Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL","title02":"Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL","journal":"Br J Haematol","issue":"2023 Sep 5. doi: 10.1111\/bjh.19087. Online ahead of print.","author":"Shen Y, Freeman JA, Kerridge I, Downe P, Naidu K, Holland J, Mulligan SP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37669920"},{"title01":"Charcot-Leyden crystals in acute myeloid leukaemia associated with basophilia","title02":"Charcot-Leyden crystals in acute myeloid leukaemia associated with basophilia","journal":"Br J Haematol","issue":"2023 Sep 5. doi: 10.1111\/bjh.19092. Online ahead of print.","author":"Chiriac R, Humbert C, Mejri A, Debliquis A, Lefebvre T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37670216"},{"title01":"Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study","title02":"Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study","journal":"Lancet Haematol","issue":"2023 Sep 6:S2352-3026(23)00212-0. doi: 10.1016\/S2352-3026(23)00212-0. Online ahead of print.","author":"Trab T, Baech J, Jakobsen LH, Husby S, Severinsen MT, Eloranta S, G\u00f8rl\u00f8v JS, J\u00f8rgensen JM, Gudbrandsdottir S, Larsen TS, Brown P, Gr\u00f8nb\u00e6k K, Smedby KE, El-Galaly TC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37689081"},{"title01":"Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation","title02":"Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation","journal":"Lancet Haematol","issue":"2023 Sep 6:S2352-3026(23)00248-X. doi: 10.1016\/S2352-3026(23)00248-X. Online ahead of print.","author":"Sureda A, Domingo-Domenech E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37689082"},{"title01":"Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy","title02":"Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy","journal":"Haematologica","issue":"2023 Sep 14. doi: 10.3324\/haematol.2021.278613. Online ahead of print.","author":"Roschewski M, Hodson DJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37706315"},{"title01":"A phase II study of interrupted and continuous dose lenalidomide in relapsed\/refractory Hodgkin lymphoma","title02":"A phase II study of interrupted and continuous dose lenalidomide in relapsed\/refractory Hodgkin lymphoma","journal":"Haematologica","issue":"2023 Sep 14. doi: 10.3324\/haematol.2022.282246. Online ahead of print.","author":"Fehniger TA, Watkins MP, Ezenwajiaku N, Wan F, Hurd DD, Cashen AF, Blum KA, Goy A, Fenske TS, Wagner-Johnston ND, Carson K, Siegel MJ, Russler-Germain D, Schneider SE, Mehta-Shah N, Kahl B, Bartlett NL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37706336"},{"title01":"Prognostic value of minimal disseminated disease assessed using digital PCR for 3'ALK assays in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma","title02":"Prognostic value of minimal disseminated disease assessed using digital PCR for 3'<i>ALK<\/i> assays in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma","journal":"Haematologica","issue":"2023 Sep 7. doi: 10.3324\/haematol.2023.282812. Online ahead of print.","author":"Fukano R, Iijima-Yamashita Y, Iwafuchi H, Nakazawa A, Saito AM, Takimoto T, Sekimizu M, Suehiro Y, Yamasaki T, Hasegawa S, Mori T, Horibe K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37675509"},{"title01":"Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas","title02":"Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas","journal":"Br J Haematol","issue":"2023 Sep 10. doi: 10.1111\/bjh.19057. Online ahead of print.","author":"Dodero A, Bramanti S, Di Trani M, Pennisi M, Ljevar S, Chiappella A, Massimo M, Guidetti A, Corrado F, Nierychlewska PM, Di Rocco A, Lorenzini D, Daoud R, De Philippis C, Santoro A, Carlo-Stella C, Corradini P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37690811"},{"title01":"Lymphoplasmacytic lymphoma presenting cold agglutinin syndrome: Clonal expansion of KMT2D and IGHV4-34 mutations after COVID-19","title02":"Lymphoplasmacytic lymphoma presenting cold agglutinin syndrome: Clonal expansion of <i>KMT2D<\/i> and <i>IGHV4-34<\/i> mutations after COVID-19","journal":"Br J Haematol","issue":"2023 Sep 11. doi: 10.1111\/bjh.19106. Online ahead of print.","author":"Hayashi K, Koyama D, Sato Y, Fukatsu M, Ikezoe T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37697431"},{"title01":"A novel SLC1A1-RIC1 fusion sensitive to asparaginase-based therapy in natural killer\/T-cell lymphoma","title02":"A novel <i>SLC1A1-RIC1<\/i> fusion sensitive to asparaginase-based therapy in natural killer\/T-cell lymphoma","journal":"Br J Haematol","issue":"2023 Sep 1. doi: 10.1111\/bjh.19066. Online ahead of print.","author":"Xiong J, Zhao WL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37658626"},{"title01":"Follicular lymphoma evolves with a surmountable dependency on acquired glycosylation motifs in the B cell receptor","title02":"Follicular lymphoma evolves with a surmountable dependency on acquired glycosylation motifs in the B cell receptor","journal":"Blood","issue":"2023 Sep 8:blood.2023020360. doi: 10.1182\/blood.2023020360. Online ahead of print.","author":"Haebe SE, Day G, Czerwinski DK, Sathe A, Grimes SM, Chen T, Long SR, Martin BA, Ozawa MG, Ji HP, Shree T, Levy R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37683139"},{"title01":"How I treat secondary CNS involvement by aggressive lymphomas","title02":"How I treat secondary CNS involvement by aggressive lymphomas","journal":"Blood","issue":"2023 Sep 13:blood.2023020168. doi: 10.1182\/blood.2023020168. Online ahead of print.","author":"Alderuccio JP, Nayak L, Cwynarski K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37702537"},{"title01":"External validity of lymphoma clinical trials","title02":"External validity of lymphoma clinical trials","journal":"Blood","issue":"2023 Aug 31;142(9):757-759.","author":"Calip GS, Royce TJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37651155"},{"title01":"Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells","title02":"Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells","journal":"Haematologica","issue":"2023 Sep 7. doi: 10.3324\/haematol.2023.283296. Online ahead of print.","author":"Kathari YK, Ahmad H, Kallen ME, Koka R, Omili D, Iraguha T, Clement J, Pham L, Khalid M, Fan X, Gebru E, Lesho P, Park E, Dishanthan N, Baker JM, Dietze KA, Hankey KG, Badros A, Yared JA, Dahiya S, Hardy NM, Kocoglu H, Luetkens T, Rapoport AP, Atanackovic D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37675514"},{"title01":"Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial","title02":"Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial","journal":"Br J Haematol","issue":"2023 Sep 10. doi: 10.1111\/bjh.19097. Online ahead of print.","author":"Kubicki T, Dytfeld D, Wr\u00f3bel T, Jamroziak K, Robak P, Czy\u017c J, Tyczy\u0144ska A, Druzd-Sitek A, Giannopoulos K, Szczepaniak T, \u0141ojko-Dankowska A, Matuszak M, Gil L, Pu\u0142a B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski \u0141, Zaucha JM, Mikulski D, Czabak O, Lahoud OB, Stefka A, Derman BA, Jakubowiak AJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37691005"},{"title01":"Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma","title02":"Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma","journal":"Br J Haematol","issue":"2023 Sep 12. doi: 10.1111\/bjh.19102. Online ahead of print.","author":"Williams CMD, Noll JE, Bradey AL, Duggan J, Wilczek VJ, Masavuli MG, Grubor-Bauk B, Panagopoulos RA, Hewett DR, Mrozik KM, Zannettino ACW, Vandyke K, Panagopoulos V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37699574"},{"title01":"PRUNE1 (located on chromosome 1q21.3) promotes multiple myeloma with 1q21 Gain by enhancing the links between purine and mitochondrion","title02":"PRUNE1 (located on chromosome 1q21.3) promotes multiple myeloma with 1q21 Gain by enhancing the links between purine and mitochondrion","journal":"Br J Haematol","issue":"2023 Sep 4. doi: 10.1111\/bjh.19088. Online ahead of print.","author":"Xu J, Wang Y, Li P, Chen C, Jiang Z, Wang X, Liu P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37666675"},{"title01":"Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study","title02":"Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study","journal":"Lancet Haematol","issue":"2023 Sep 6:S2352-3026(23)00212-0. doi: 10.1016\/S2352-3026(23)00212-0. Online ahead of print.","author":"Trab T, Baech J, Jakobsen LH, Husby S, Severinsen MT, Eloranta S, G\u00f8rl\u00f8v JS, J\u00f8rgensen JM, Gudbrandsdottir S, Larsen TS, Brown P, Gr\u00f8nb\u00e6k K, Smedby KE, El-Galaly TC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37689081"},{"title01":"Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation","title02":"Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation","journal":"Lancet Haematol","issue":"2023 Sep 6:S2352-3026(23)00248-X. doi: 10.1016\/S2352-3026(23)00248-X. Online ahead of print.","author":"Sureda A, Domingo-Domenech E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37689082"},{"title01":"Amphiregulin as monitoring biomarker for life-threatening acute graft-versushost disease: secondary analysis of two prospective clinical trials","title02":"Amphiregulin as monitoring biomarker for life-threatening acute graft-versushost disease: secondary analysis of two prospective clinical trials","journal":"Haematologica","issue":"2023 Sep 14. doi: 10.3324\/haematol.2023.283215. Online ahead of print.","author":"Holtan SG, El Jurdi N, Rashidi A, Betts BC, Demorest C, Galvin JP, MacMillan ML, Weisdorf DJ, Panoskaltsis-Mortari A, Pratta MA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37706330"},{"title01":"Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant","title02":"Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant","journal":"Haematologica","issue":"2023 Sep 14. doi: 10.3324\/haematol.2023.283740. Online ahead of print.","author":"Begna KH, Abdallah NH, Janania-Martinez M, Mangaonkar AA, Rangan A, Herrick JL, Gangat N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37706335"},{"title01":"Treg-targeted IL-2\/anti-IL-2 complex controls graft-versus-host disease and supports anti-tumor effect in allogeneic hematopoietic stem cell transplantation","title02":"Treg-targeted IL-2\/anti-IL-2 complex controls graft-<i>versus<\/i>-host disease and supports anti-tumor effect in allogeneic hematopoietic stem cell transplantation","journal":"Haematologica","issue":"2023 Sep 14. doi: 10.3324\/haematol.2022.282653. Online ahead of print.","author":"Thiolat A, Pilon C, Caudana P, Moatti A, To NH, Sedlik C, Leclerc M, Maury S, Piaggio E, Cohen JL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37706355"},{"title01":"Uniform conditioning regardless of donor in bone marrow transplantation for severe aplastic anemia","title02":"Uniform conditioning regardless of donor in bone marrow transplantation for severe aplastic anemia","journal":"Haematologica","issue":"2023 Sep 7. doi: 10.3324\/haematol.2023.284022. Online ahead of print.","author":"DeZern AE, Zahurak M, Jones RJ, Brodsky RA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37675516"},{"title01":"Major incompatible red blood cell transfusions prior to bone marrow transplantation: Not worth the risk","title02":"Major incompatible red blood cell transfusions prior to bone marrow transplantation: Not worth the risk","journal":"Br J Haematol","issue":"2023 Sep 8. doi: 10.1111\/bjh.19101. Online ahead of print.","author":"Haspel RL, McKenna DH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37681639"},{"title01":"Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial","title02":"Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial","journal":"Br J Haematol","issue":"2023 Sep 10. doi: 10.1111\/bjh.19097. Online ahead of print.","author":"Kubicki T, Dytfeld D, Wr\u00f3bel T, Jamroziak K, Robak P, Czy\u017c J, Tyczy\u0144ska A, Druzd-Sitek A, Giannopoulos K, Szczepaniak T, \u0141ojko-Dankowska A, Matuszak M, Gil L, Pu\u0142a B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski \u0141, Zaucha JM, Mikulski D, Czabak O, Lahoud OB, Stefka A, Derman BA, Jakubowiak AJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37691005"},{"title01":"Long-term follow-up of haploidentical haematopoietic stem cell transplantation in paediatric patients with high-risk acute myeloid leukaemia: Report from a single centre","title02":"Long-term follow-up of haploidentical haematopoietic stem cell transplantation in paediatric patients with high-risk acute myeloid leukaemia: Report from a single centre","journal":"Br J Haematol","issue":"2023 Sep 2. doi: 10.1111\/bjh.19086. Online ahead of print.","author":"Bai L, Zhang ZX, Hu GH, Cheng YF, Suo P, Wang Y, Yan CH, Sun YQ, Chen YH, Chen H, Liu KY, Xu LP, Huang XJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37658699"},{"title01":"Response to Haspel and McKenna &#8216;Major incompatible red blood cell transfusions prior to bone marrow transplantation: Not worth the risk&#8217;","title02":"Response to Haspel and McKenna &#8216;Major incompatible red blood cell transfusions prior to bone marrow transplantation: Not worth the risk&#8217;","journal":"Br J Haematol","issue":"2023 Sep 7. doi: 10.1111\/bjh.19100. Online ahead of print.","author":"Jarisch A, Bonig H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37675578"},{"title01":"Spatial Transcriptomics Reveals Distinct Tissue Niches Linked with Steroid Responsiveness in Acute Gastrointestinal GVHD","title02":"Spatial Transcriptomics Reveals Distinct Tissue Niches Linked with Steroid Responsiveness in Acute Gastrointestinal GVHD","journal":"Blood","issue":"2023 Sep 12:blood.2023020644. doi: 10.1182\/blood.2023020644. Online ahead of print.","author":"Patel BK, Raabe MJ, Lang ER, Song Y, Lu C, Deshpande V, Nieman LT, Aryee MJ, Chen YB, Ting DT, DeFilipp Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37699201"},{"title01":"Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study","title02":"Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study","journal":"Lancet Haematol","issue":"2023 Sep 6:S2352-3026(23)00212-0. doi: 10.1016\/S2352-3026(23)00212-0. Online ahead of print.","author":"Trab T, Baech J, Jakobsen LH, Husby S, Severinsen MT, Eloranta S, G\u00f8rl\u00f8v JS, J\u00f8rgensen JM, Gudbrandsdottir S, Larsen TS, Brown P, Gr\u00f8nb\u00e6k K, Smedby KE, El-Galaly TC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37689081"},{"title01":"Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation","title02":"Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation","journal":"Lancet Haematol","issue":"2023 Sep 6:S2352-3026(23)00248-X. doi: 10.1016\/S2352-3026(23)00248-X. Online ahead of print.","author":"Sureda A, Domingo-Domenech E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37689082"},{"title01":"Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant","title02":"Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant","journal":"Haematologica","issue":"2023 Sep 14. doi: 10.3324\/haematol.2023.283740. Online ahead of print.","author":"Begna KH, Abdallah NH, Janania-Martinez M, Mangaonkar AA, Rangan A, Herrick JL, Gangat N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37706335"},{"title01":"Treg-targeted IL-2\/anti-IL-2 complex controls graft-versus-host disease and supports anti-tumor effect in allogeneic hematopoietic stem cell transplantation","title02":"Treg-targeted IL-2\/anti-IL-2 complex controls graft-<i>versus<\/i>-host disease and supports anti-tumor effect in allogeneic hematopoietic stem cell transplantation","journal":"Haematologica","issue":"2023 Sep 14. doi: 10.3324\/haematol.2022.282653. Online ahead of print.","author":"Thiolat A, Pilon C, Caudana P, Moatti A, To NH, Sedlik C, Leclerc M, Maury S, Piaggio E, Cohen JL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37706355"},{"title01":"Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial","title02":"Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial","journal":"Br J Haematol","issue":"2023 Sep 10. doi: 10.1111\/bjh.19097. Online ahead of print.","author":"Kubicki T, Dytfeld D, Wr\u00f3bel T, Jamroziak K, Robak P, Czy\u017c J, Tyczy\u0144ska A, Druzd-Sitek A, Giannopoulos K, Szczepaniak T, \u0141ojko-Dankowska A, Matuszak M, Gil L, Pu\u0142a B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski \u0141, Zaucha JM, Mikulski D, Czabak O, Lahoud OB, Stefka A, Derman BA, Jakubowiak AJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37691005"},{"title01":"Long-term follow-up of haploidentical haematopoietic stem cell transplantation in paediatric patients with high-risk acute myeloid leukaemia: Report from a single centre","title02":"Long-term follow-up of haploidentical haematopoietic stem cell transplantation in paediatric patients with high-risk acute myeloid leukaemia: Report from a single centre","journal":"Br J Haematol","issue":"2023 Sep 2. doi: 10.1111\/bjh.19086. Online ahead of print.","author":"Bai L, Zhang ZX, Hu GH, Cheng YF, Suo P, Wang Y, Yan CH, Sun YQ, Chen YH, Chen H, Liu KY, Xu LP, Huang XJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37658699"},{"title01":"Neutral sphingomyelinase blockade enhances hematopoietic stem cell fitness through an integrated stress response","title02":"Neutral sphingomyelinase blockade enhances hematopoietic stem cell fitness through an integrated stress response","journal":"Blood","issue":"2023 Sep 12:blood.2023022147. doi: 10.1182\/blood.2023022147. Online ahead of print.","author":"Hurwitz SN, Jung SK, Kobulsky DR, Fazelinia H, Spruce LA, Baltasar-P\u00e9rez E, Groen N, Mesaros C, Kurre P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37699202"},{"title01":"Tackling the enormous global burden of anaemia","title02":"Tackling the enormous global burden of anaemia","journal":"Lancet Haematol","issue":"2023 Sep;10(9):e695.","author":"The Lancet Haematology.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37652594"},{"title01":"Uniform conditioning regardless of donor in bone marrow transplantation for severe aplastic anemia","title02":"Uniform conditioning regardless of donor in bone marrow transplantation for severe aplastic anemia","journal":"Haematologica","issue":"2023 Sep 7. doi: 10.3324\/haematol.2023.284022. Online ahead of print.","author":"DeZern AE, Zahurak M, Jones RJ, Brodsky RA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37675516"},{"title01":"First description of bone marrow failure syndrome in Spain caused by mutations in the ERCC6L2 gene","title02":"First description of bone marrow failure syndrome in Spain caused by mutations in the ERCC6L2 gene","journal":"Br J Haematol","issue":"2023 Sep 11. doi: 10.1111\/bjh.19050. Online ahead of print.","author":"Bandini P, Borr\u00e0s N, Fernandez Mellid E, Martin-Fernandez L, Melero Valent\u00edn P, Comes N, Ram\u00edrez L, Cadahia Fern\u00e1ndez P, Rodr\u00edguez Ruiz M, Perez Encinas MM, Vidal F, Corrales I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37696499"},{"title01":"A longitudinal analysis of paroxysmal nocturnal haemoglobinuria-type cells in patients with bone marrow failure: Results of a prospective multi-centre study in Japan","title02":"A longitudinal analysis of paroxysmal nocturnal haemoglobinuria-type cells in patients with bone marrow failure: Results of a prospective multi-centre study in Japan","journal":"Br J Haematol","issue":"2023 Aug 31. doi: 10.1111\/bjh.19048. Online ahead of print.","author":"Ishiyama K, Yonemura Y, Kawaguchi T, Hosokawa K, Sugimori C, Ueda Y, Takamori H, Obara N, Noji H, Shirasugi Y, Ando K, Shichishima T, Ninomiya H, Chiba S, Nishimura JI, Kanakura Y, Nakao S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37654088"},{"title01":"Intramuscular anti-D treatment for immune thrombocytopenia","title02":"Intramuscular anti-D treatment for immune thrombocytopenia","journal":"Br J Haematol","issue":"2023 Sep 8. doi: 10.1111\/bjh.19091. Online ahead of print.","author":"Woo EJ, Kaushal M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37681547"},{"title01":"Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies","title02":"Myeloid lineage switch in <i>KMT2A<\/i>-rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies","journal":"Haematologica","issue":"2023 Aug 31. doi: 10.3324\/haematol.2023.283705. Online ahead of print.","author":"Bataller A, Abuasab T, McCall D, Wang W, Cuglievan B, Issa GC, Jabbour E, Short N, DiNardo CD, Tang G, Garcia-Manero G, Kantarjian HM, Sasaki K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646654"},{"title01":"SUMOylation inhibitor TAK-981 (subasumstat) synergizes with 5-azacitidine in preclinical models of acute myeloid leukemia","title02":"SUMOylation inhibitor TAK-981 (subasumstat) synergizes with 5-azacitidine in preclinical models of acute myeloid leukemia","journal":"Haematologica","issue":"2023 Aug 24. doi: 10.3324\/haematol.2023.282704. Online ahead of print.","author":"Gabellier L, De Toledo M, Chakraborty M, Akl D, Hallal R, Aqrouq M, Buonocore G, Recasens-Zorzo C, Cartron G, Delort A, Piechaczyk M, Temp\u00e9 D, Bossis G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37608777"},{"title01":"miR-30e-5p regulates leukemia stem cell self-renewal through the Cyb561\/ROS signaling pathway","title02":"miR-30e-5p regulates leukemia stem cell self-renewal through the Cyb561\/ROS signaling pathway","journal":"Haematologica","issue":"2023 Aug 17. doi: 10.3324\/haematol.2023.282837. Online ahead of print.","author":"Ge Y, Hong M, Zhang Y, Wang J, Li L, Zhu H, Sheng Y, Wu WS, Zhang Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37584287"},{"title01":"First mouse model of infant acute myeloid leukemia with t(7;12)(q36;p17)","title02":"First mouse model of infant acute myeloid leukemia with t(7;12)(q36;p17)","journal":"Haematologica","issue":"2023 Aug 17. doi: 10.3324\/haematol.2023.283659. Online ahead of print.","author":"Jevtic Z, Schwaller J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37584296"},{"title01":"Prognostic impact of FLT3-ITD mutation on NPM1+ acute myeloid leukaemia patients and related molecular mechanisms","title02":"Prognostic impact of FLT3-ITD mutation on <i>NPM1<\/i><sup>+<\/sup> acute myeloid leukaemia patients and related molecular mechanisms","journal":"Br J Haematol","issue":"2023 Aug 25. doi: 10.1111\/bjh.18973. Online ahead of print.","author":"Pan X, Chang Y, Ruan G, Wei F, Jiang H, Jiang Q, Huang X, Zhao X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37621257"},{"title01":"Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia","title02":"Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia","journal":"Br J Haematol","issue":"2023 Aug 22. doi: 10.1111\/bjh.19060. Online ahead of print.","author":"Montalban-Bravo G, Kanagal-Shamanna R, Li Z, Hammond D, Chien K, Rodriguez-Sevilla JJ, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37608562"},{"title01":"Demographic and clinical characteristics of acute myeloid leukaemia diagnosed and treated at the tertiary level in Afghanistan","title02":"Demographic and clinical characteristics of acute myeloid leukaemia diagnosed and treated at the tertiary level in Afghanistan","journal":"Br J Haematol","issue":"2023 Aug 23. doi: 10.1111\/bjh.19029. Online ahead of print.","author":"Noor S, Haidary AM, Yosufzai AW, Niazai M, Noor S, Nasir N, Shinwari A, Saadaat R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37609793"},{"title01":"Acute myeloid leukaemia in Afghanistan: Understanding an unfamiliar landscape","title02":"Acute myeloid leukaemia in Afghanistan: Understanding an unfamiliar landscape","journal":"Br J Haematol","issue":"2023 Aug 23. doi: 10.1111\/bjh.19063. Online ahead of print.","author":"Hills RK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37612135"},{"title01":"XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling","title02":"<i>XPO1<\/i> mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling","journal":"Br J Haematol","issue":"2023 Aug 14. doi: 10.1111\/bjh.19052. Online ahead of print.","author":"Moia R, di Terzi Bergamo L, Talotta D, Bomben R, Forestieri G, Spina V, Bruscaggin A, Cosentino C, Almasri M, Dondolin R, Bittolo T, Zucchetto A, Baldoni S, Del Giudice I, Mauro FR, Maffei R, Chiarenza A, Tafuri A, Laureana R, Del Principe MI, Zaja F, D'Arena G, Olivieri J, Rasi S, Mahmoud A, Al Essa W, Awikeh B, Kogila S, Bellia M, Mouhssine S, Sportoletti P, Marasca R, Scarf\u00f2 L, Ghia P, Gattei V, Fo\u00e0 R, Rossi D, Gaidano G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37580908"},{"title01":"Lineage-specific detection of residual disease predicts relapse in chronic myeloid leukemia patients stopping therapy","title02":"Lineage-specific detection of residual disease predicts relapse in chronic myeloid leukemia patients stopping therapy","journal":"Blood","issue":"2023 Aug 24:blood.2023021119. doi: 10.1182\/blood.2023021119. Online ahead of print.","author":"Pagani IS, Shanmuganathan N, Dang P, Saunders VA, Grose R, Kok CH, James J, Tolland M, Braley JA, Altamura HK, Yeung DT, Branford S, Yong AS, Hughes TP, Ross DM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37616555"},{"title01":"Cdc73 protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress","title02":"<i>Cdc73<\/i> protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress","journal":"Blood","issue":"2023 Aug 24:blood.2023020144. doi: 10.1182\/blood.2023020144. Online ahead of print.","author":"Melnick AF, Mullin C, Lin K, McCarter AC, Liang S, Liu YE, Wang Q, Jerome NA, Choe E, Kunnath N, Bodanapu G, Akter F, Magnuson B, Kumar S, Lombard DB, Muntean AG, Ljungman M, Sekiguchi J, Ryan RJ, Chiang MY.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37616559"},{"title01":"Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia","title02":"Identifying <i>STRN3-RARA<\/i> as a new fusion gene for acute promyelocytic leukemia","journal":"Blood","issue":"2023 Aug 25:blood.2023020619. doi: 10.1182\/blood.2023020619. Online ahead of print.","author":"Zhang Q, Li H, Chen X, Gu F, Zhang L, Zhang L, Chen T, Chen Q, Meng W, Wu Y, Chang H, Liu T, Chen C, Ma H, Liu Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37624915"},{"title01":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based non-intensive therapy","title02":"Molecular MRD is strongly prognostic in patients with <i>NPM1<\/i>-mutated AML receiving venetoclax-based non-intensive therapy","journal":"Blood","issue":"2023 Aug 30:blood.2023021579. doi: 10.1182\/blood.2023021579. Online ahead of print.","author":"Othman J, Tiong IS, O'Nions J, Dennis M, Mokretar K, Ivey A, Austin MJ, Latif AL, Amer M, Chan WY, Crawley CR, Crolla F, Cross JW, Dang R, Elliot J, Fong CY, Galli S, Gallipoli P, Hogan F, Kalkur P, Khan AB, Krishnamurthy P, Laurie J, Loo S, Marshall S, Mehta P, Murthy V, Nagumantry S, Pillai S, Potter N, Sellar RS, Taylor T, Zhao R, Russell NH, Wei AH, Dillon R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37647641"},{"title01":"Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML:a randomized, placebo-controlled study by the ALLG","title02":"Sorafenib plus intensive chemotherapy in newly diagnosed <i>FLT3<\/i>-ITD AML:a randomized, placebo-controlled study by the ALLG","journal":"Blood","issue":"2023 Aug 30:blood.2023020301. doi: 10.1182\/blood.2023020301. Online ahead of print.","author":"Loo S, Roberts AW, Anstee NS, Kennedy GA, He SZ, Schwarer AP, Enjeti AK, D'Rozario J, Marlton P, Bilmon I, Taper JM, Cull G, Tiley C, Verner E, Hahn U, Hiwase DK, Iland HJ, Murphy NE, Ramanathan S, Reynolds J, Ong DM, Tiong IS, Wall M, Murray M, Rawling T, Leadbetter J, Rowley L, Latimer M, Yuen SLS, Ting SB, Fong CY, Morris KL, Bajel A, Seymour JF, Levis MJ, Wei AH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37647654"},{"title01":"TP53 status and impact on AML prognosis within the ELN 2022 risk classification","title02":"<i>TP53<\/i> status and impact on AML prognosis within the ELN 2022 risk classification","journal":"Blood","issue":"2023 Aug 30:blood.2023020855. doi: 10.1182\/blood.2023020855. Online ahead of print.","author":"Fleming SA, Tsai XC, Morris R, Hou HA, Wei AH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37647854"},{"title01":"Sustained remissions in CLL after frontline FCR treatment with very long-term follow-up","title02":"Sustained remissions in CLL after frontline FCR treatment with very long-term follow-up","journal":"Blood","issue":"2023 Aug 18:blood.2023020158. doi: 10.1182\/blood.2023020158. Online ahead of print.","author":"Thompson PA, Bazinet A, Wierda WG, Tam CS, O'Brien SM, Saha S, Peterson C, Plunkett W, Keating MJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37595283"},{"title01":"Fractionated Versus Single Dose Gemtuzumab Ozogamicin with Determinants of Benefit in Older AML: UK NCRI AML18 Trial","title02":"Fractionated Versus Single Dose Gemtuzumab Ozogamicin with Determinants of Benefit in Older AML: UK NCRI AML18 Trial","journal":"Blood","issue":"2023 Aug 18:blood.2023020630. doi: 10.1182\/blood.2023020630. Online ahead of print.","author":"Freeman SD, Thomas A, Thomas I, Hills RK, Vyas P, Gilkes AF, Metzner M, Jakobsen NA, Kennedy A, Moore AR, Marquez-Almuina N, Burns S, King S, Andrew G, Gallagher KME, Sellar RS, Cahalin PA, Weber D, Dennis M, Mehta P, Knapper S, Russell NH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37595359"},{"title01":"Food for thought (and CML survival)","title02":"Food for thought (and CML survival)","journal":"Blood","issue":"2023 Aug 10;142(6):502-504.","author":"Sezaki M, Huang G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37561542"},{"title01":"Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma","title02":"Frequent <i>ZNF217<\/i> mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma","journal":"Leukemia","issue":"2023 Aug 30. doi: 10.1038\/s41375-023-02013-9. Online ahead of print.","author":"Briest F, Noerenberg D, Hennch C, Yoshida K, Hablesreiter R, Nimo J, Sasca D, Kirchner M, Mansouri L, Inoue Y, Wiegand L, Staiger AM, Casadei B, Korkolopoulou P, Weiner J, Lopez-Guillermo A, Warth A, Schneider T, Nagy \u00c1, Klapper W, Hummel M, Kanellis G, Anagnostopoulos I, Mertins P, Bullinger L, Rosenquist R, Vassilakopoulos TP, Ott G, Ogawa S, Damm F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37648814"},{"title01":"Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma","title02":"Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma","journal":"Leukemia","issue":"2023 Aug 19. doi: 10.1038\/s41375-023-02006-8. Online ahead of print.","author":"Sircar A, Singh S, Xu-Monette ZY, Coyle KM, Hilton LK, Chavdoula E, Ranganathan P, Jain N, Hanel W, Tsichlis P, Alinari L, Peterson BR, Tao J, Muthusamy N, Baiocchi R, Epperla N, Young KH, Morin R, Sehgal L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37598282"},{"title01":"Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms","title02":"Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms","journal":"Leukemia","issue":"2023 Aug 10. doi: 10.1038\/s41375-023-01995-w. Online ahead of print.","author":"Kalmbach S, Grau M, Zapukhlyak M, Leich E, Jurinovic V, Hoster E, Staiger AM, Kurz KS, Weigert O, Gaitzsch E, Passerini V, Engelhard M, Herfarth K, Beiske K, Micci F, M\u00f6ller P, Bernd HW, Feller AC, Klapper W, Stein H, Hansmann ML, Hartmann S, Dreyling M, Holte H, Lenz G, Rosenwald A, Ott G, Horn H; German Lymphoma Alliance (GLA).","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37563306"},{"title01":"CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma","title02":"CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma","journal":"Leukemia","issue":"2023 Aug 12. doi: 10.1038\/s41375-023-01997-8. Online ahead of print.","author":"Parameswaran N, Luo L, Zhang L, Chen J, DiFilippo FP, Androjna C, Fox DA, Ondrejka SL, Hsi ED, Jagadeesh D, Lindner DJ, Lin F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37573404"},{"title01":"Author gender representation of journal reviews and editorials on lymphoma (2017-22)","title02":"Author gender representation of journal reviews and editorials on lymphoma (2017-22)","journal":"Lancet","issue":"2023 Aug 12;402(10401):523-525.","author":"Hawkes EA, Trotman J, Casulo C, Smith SM, LaCasce A; international Women in Lymphoma Steering Committee.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37573074"},{"title01":"Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy","title02":"Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy","journal":"Haematologica","issue":"2023 Aug 31. doi: 10.3324\/haematol.2023.283727. Online ahead of print.","author":"Xie Z, Lasho T, Khurana A, Ferrer A, Finke C, Mangaonkar AA, Ansell S, Fernandez J, Shah MV, Al-Kali A, Gangat N, Abeykoon J, Witzig TE, Patnaik MM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646653"},{"title01":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study","title02":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study","journal":"Haematologica","issue":"2023 Aug 31. doi: 10.3324\/haematol.2023.283459. Online ahead of print.","author":"Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646659"},{"title01":"Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4068 patients","title02":"Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4068 patients","journal":"Haematologica","issue":"2023 Aug 31. doi: 10.3324\/haematol.2023.283446. Online ahead of print.","author":"Cook MR, Williams LS, Dorris CS, Luo Y, Makambi K, Dunleavy K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646662"},{"title01":"MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53\/p53 - a Nordic Lymphoma Group study","title02":"MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and <i>TP53<\/i>\/p53 - a Nordic Lymphoma Group study","journal":"Haematologica","issue":"2023 Aug 31. doi: 10.3324\/haematol.2023.283352. Online ahead of print.","author":"Rodrigues JM, Hollander P, Schmidt L, Gkika E, Razmara M, Kumar D, Geisler C, Gr\u00f8nb\u00e6k K, Eskelund CW, R\u00e4ty R, Kolstad A, Sundstr\u00f6m C, Glimelius I, Porwit A, Jerkeman M, Ek S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646663"},{"title01":"Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase II L-MIND study","title02":"Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase II L-MIND study","journal":"Haematologica","issue":"2023 Aug 31. doi: 10.3324\/haematol.2023.283480. Online ahead of print.","author":"Duell J, Abrisqueta P, Andre M, Gaidano G, Gonzales-Barca E, Jurczak W, Kalakonda N, Liberati AM, Maddocks KJ, Menne T, Nagy Z, Tournilhac O, Kuffer C, Bakuli A, Amin A, Gurbanov K, Salles G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646664"},{"title01":"Survival disparities between children and adolescents and young adults for the major subtypes of non-Hodgkin lymphoma in the Netherlands: a large population-based study","title02":"Survival disparities between children and adolescents and young adults for the major subtypes of non-Hodgkin lymphoma in the Netherlands: a large population-based study","journal":"Haematologica","issue":"2023 Aug 31. doi: 10.3324\/haematol.2023.283379. Online ahead of print.","author":"Schulpen M, Beishuizen A, Chamuleau MED, Dinmohamed AG, Meyer-Wentrup FAG, Vormoor HJ, Van der Wagen LE, Minnema MC, Loeffen JLC, Karim-Kos HE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646666"},{"title01":"Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study","title02":"Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study","journal":"Haematologica","issue":"2023 Aug 31. doi: 10.3324\/haematol.2023.283162. Online ahead of print.","author":"Gordon LI, Liu FF, Braverman J, Hoda D, Ghosh N, Hamadani M, Hildebrandt GC, Peng L, Guo S, Shi L, Sehgal A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646670"},{"title01":"Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation","title02":"Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation","journal":"Haematologica","issue":"2023 Aug 31. doi: 10.3324\/haematol.2023.282898. Online ahead of print.","author":"Epstein-Peterson ZD, Drill E, Aypar U, Batlevi CL, Caron P, Dogan A, Drullinsky P, Gerecitano J, Hamlin PA, Ho C, Jacob A, Joseph A, Laraque L, Matasar MJ, Moskowitz AJ, Moskowitz CH, Mullins C, Owens C, Salles G, Sch\u00f6der H, Straus DJ, Younes A, Zelenetz AD, Kumar A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646671"},{"title01":"Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET\/CT and good long-term outcomes","title02":"Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET\/CT and good long-term outcomes","journal":"Haematologica","issue":"2023 Aug 31. doi: 10.3324\/haematol.2022.282643. Online ahead of print.","author":"Ghione P, Ahsanuddin S, Luttwak E, Varela SB, Nakajima R, Michaud L, Gupta K, Navitski A, Straus D, Palomba ML, Moskowitz A, Noy A, Hamlin P, Matasar M, Kumar A, Falchi L, Yahalom J, Horwitz S, Zelenetz A, Younes A, Salles G, Sch\u00f6der H, Joffe E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646672"},{"title01":"Distinct t(14;19) translocation patterns in atypical chronic lymphocytic leukemia and marginal zone lymphomas","title02":"Distinct t(14;19) translocation patterns in atypical chronic lymphocytic leukemia and marginal zone lymphomas","journal":"Haematologica","issue":"2023 Aug 24. doi: 10.3324\/haematol.2023.283975. Online ahead of print.","author":"K\u00fcppers R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37608774"},{"title01":"Angioimmunoblastic T-cell lymphoma: Novel recurrent mutations and prognostic biomarkers by cell-free DNA profiling","title02":"Angioimmunoblastic T-cell lymphoma: Novel recurrent mutations and prognostic biomarkers by cell-free DNA profiling","journal":"Br J Haematol","issue":"2023 Aug 30. doi: 10.1111\/bjh.19089. Online ahead of print.","author":"Zhang C, Mou B, Xu J, Wang J, Liu Q, Yang Y, Tang W, Zhong X, Xu C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646306"},{"title01":"Impact of GVHD on lymphoma progression: Nationwide study from Japanese Society for Transplantation and Cellular Therapy","title02":"Impact of GVHD on lymphoma progression: Nationwide study from Japanese Society for Transplantation and Cellular Therapy","journal":"Br J Haematol","issue":"2023 Aug 23. doi: 10.1111\/bjh.19041. Online ahead of print.","author":"Watanabe M, Kanda J, Fukuda T, Uchida N, Ikegame K, Kataoka K, Kobayashi H, Ara T, Ishikawa J, Matsuoka KI, Sugio Y, Nakazawa H, Ikeda T, Atsuta Y, Kondo E, Suzuki R; Japanese Society for Transplantation and Cellular Therapy, Adult Lymphoma Working Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37614023"},{"title01":"Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed\/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study","title02":"Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed\/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study","journal":"Haematologica","issue":"Haematologica. 2023 Aug 31. doi: 10.3324\/haematol.2023.283509. Online ahead of print.","author":"Pour L, Szarejko M, Bila J, Schjesvold FH, Spicka I, Maisnar V, Jurczyszyn A, Grudeva-Popova Z, H\u00e1jek R, Usenko G, Thuresson M, Norin S, Jarefors S, Bakker NA, Richardson PG, Mateos MV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646660"},{"title01":"Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling","title02":"Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling","journal":"Haematologica","issue":"Haematologica. 2023 Aug 31. doi: 10.3324\/haematol.2023.283445. Online ahead of print.","author":"Cardona-Benavides IJ, Misiewicz-Krzeminska I, Rojas EA, De Ram\u00f3n C, Sanz-Solas A, Isidro I, Quwaider D, L\u00f3pez-Guerrero AM, Cuadrado M, Calasanz MJ, Rosi\u00f1ol L, Mart\u00ednez-L\u00f3pez J, San Miguel JF, Mateos MV, Corchete LA, Guti\u00e9rrez NC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646661"},{"title01":"Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma","title02":"Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma","journal":"Haematologica","issue":"2023 Aug 24. doi: 10.3324\/haematol.2022.282624. Online ahead of print.","author":"Richardson PG, Durie BG, Rosi\u00f1ol L, Mateos MV, Dispenzieri A, Moreau P, Kumar S, Raje N, Munshi N, Laubach JP, O'Gorman P, O'Donnell E, Voorhees P, Facon T, Blad\u00e9 J, Lonial S, Perrot A, Anderson KC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37608773"},{"title01":"Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma","title02":"Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma","journal":"Haematologica","issue":"2023 Aug 24. doi: 10.3324\/haematol.2023.283200. Online ahead of print.","author":"Garcia JB, Storti P, Iannozzi NT, Marchica V, Agnelli L, Toscani D, Franceschi V, Todaro G, Sammarelli G, Notarfranchi L, Scita M, Palma BD, Raimondi V, Lungu O, Pruneri G, Donofrio G, Giuliani N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37608776"},{"title01":"In-depth cytogenetic and immunohistochemical analysis in a real world cohort &#8211; reconsidering the role of primary and secondary aberrations in multiple myeloma","title02":"In-depth cytogenetic and immunohistochemical analysis in a real world cohort &#8211; reconsidering the role of primary and secondary aberrations in multiple myeloma","journal":"Haematologica","issue":"2023 Aug 17. doi: 10.3324\/haematol.2023.283142. Online ahead of print.","author":"Wenger S, Pantic M, Ihorst G, Cysar S, Calba MA, Greil C, W\u00e4sch R, Engelhardt M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37584288"},{"title01":"Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis","title02":"Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis","journal":"Haematologica","issue":"2023 Aug 17. doi: 10.3324\/haematol.2023.283073. Online ahead of print.","author":"Facon T, Moreau P, Baker R, Min CK, Leleu X, Mohty M, Karlin L, Armstrong NM, Tekle C, Schwab S, Risse ML, Martin T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37584290"},{"title01":"Venous thromboembolism in multiple myeloma: Increasing evidence in support of direct oral anticoagulants","title02":"Venous thromboembolism in multiple myeloma: Increasing evidence in support of direct oral anticoagulants","journal":"Br J Haematol","issue":"2023 Aug 15. doi: 10.1111\/bjh.19056. Online ahead of print.","author":"Swan D, Comerford C, Quinn J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37581247"},{"title01":"Tumour-derived exosomes promote the induction of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells by delivering miR-106a-5p and miR-146a-5p in multiple myeloma","title02":"Tumour-derived exosomes promote the induction of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells by delivering miR-106a-5p and miR-146a-5p in multiple myeloma","journal":"Br J Haematol","issue":"2023 Aug 16. doi: 10.1111\/bjh.19049. Online ahead of print.","author":"Mizuhara K, Shimura Y, Tsukamoto T, Kanai A, Kuwahara-Ota S, Yamaguchi J, Muramatsu A, Okamoto H, Taminishi-Katsuragawa Y, Kawaji-Kanayama Y, Isa R, Mizutani S, Inaba T, Kuroda J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37584109"},{"title01":"Exploiting the CD200-CD200R Immune Checkpoint Axis in Multiple Myeloma to Enhance CAR-T Therapy","title02":"Exploiting the CD200-CD200R Immune Checkpoint Axis in Multiple Myeloma to Enhance CAR-T Therapy","journal":"Blood","issue":"2023 Aug 24:blood.2022018658. doi: 10.1182\/blood.2022018658. Online ahead of print.","author":"Tang Y, Liu W, Kadu S, Johnson O, Hasanali ZS, Kelly AR, Shestov AA, Greenblat E, Holmes M, Wang LP, Shih N, O'Connor RS, Garfall A, Allman D, Vogl DT, Cohen AD, June CH, Sheppard NC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37616575"},{"title01":"Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation","title02":"Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation","journal":"Leukemia","issue":"2023 Aug 11. doi: 10.1038\/s41375-023-01998-7. Online ahead of print.","author":"N\u00f8rgaard JN, Abildgaard N, Lys\u00e9n A, Tsykunova G, Vangsted AJ, Jo\u00e3o C, Remen N, Nielsen LK, Osnes L, Stokke C, Connelly JP, Revheim MR; Nordic Myeloma Study Group (NMSG); Schjesvold F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37568010"},{"title01":"Immune recognition of porcine organs transplanted into humans","title02":"Immune recognition of porcine organs transplanted into humans","journal":"Lancet","issue":"2023 Aug 17:S0140-6736(23)01556-8. doi: 10.1016\/S0140-6736(23)01556-8. Online ahead of print.","author":"Shaver CM, Bacchetta M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37598689"},{"title01":"Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study","title02":"Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study","journal":"J Clin Oncol","issue":"2023 Aug 22:JCO2300866. doi: 10.1200\/JCO.23.00866. Online ahead of print.","author":"Versluis J, Saber W, Tsai HK, Gibson CJ, Dillon LW, Mishra A, McGuirk J, Maziarz RT, Westervelt P, Hegde P, Mukherjee D, Martens MJ, Logan B, Horowitz M, Hourigan CS, Nakamura R, Cutler C, Lindsley RC; Blood and Marrow Transplant Clinical Trials Network.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37607457"},{"title01":"What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?","title02":"What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?","journal":"J Clin Oncol","issue":"2023 Aug 23:JCO2202868. doi: 10.1200\/JCO.22.02868. Online ahead of print.","author":"DeWolf S, Tallman MS, Rowe JM, Salman MY.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37611216"},{"title01":"Which is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome?","title02":"Which is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome?","journal":"Haematologica","issue":"2023 Aug 31. doi: 10.3324\/haematol.2023.283719. Online ahead of print.","author":"Autore F, Bramanti S, Lessi F, Innocenti I, Galli E, Rocchi S, Ribolla R, Derudas D, Oliva S, Stefanoni P, Marcatti M, Schenone A, La Nasa G, Crippa C, Zamagni E, Riva M, Mazza R, Mannina D, Sica S, Bacigalupo A, Laurenti L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646655"},{"title01":"Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study","title02":"Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study","journal":"Haematologica","issue":"2023 Aug 31. doi: 10.3324\/haematol.2023.283175. Online ahead of print.","author":"Weller JF, Lengerke C, Finke J, Schetelig J, Platzbecker U, Einsele H, Schroeder T, Faul C, Stelljes M, Dreger P, Blau IW, Wulf G, Tischer J, Scheid C, Elmaagacli A, Neidlinger H, Flossdorf S, Bornh\u00e4user M, Bethge W, Fleischhauer K, Kr\u00f6ger N, De Wreede LC, Christopeit M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646665"},{"title01":"Red cell distribution width as a new prognostic biomarker in refractory chronic graft-versus-host disease","title02":"Red cell distribution width as a new prognostic biomarker in refractory chronic graft-versus-host disease","journal":"Haematologica","issue":"2023 Aug 17. doi: 10.3324\/haematol.2023.283646. Online ahead of print.","author":"Schulz E, Pirsl F, Holtzman NG, Beshensky D, Cowen EW, Mitchell SA, Steinberg SM, Pavletic SZ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37584292"},{"title01":"SARS-CoV-2 vaccination in 361 non-transplanted patients with aplastic anemia and\/or paroxysmal nocturnal hemoglobinuria","title02":"SARS-CoV-2 vaccination in 361 non-transplanted patients with aplastic anemia and\/or paroxysmal nocturnal hemoglobinuria","journal":"Haematologica","issue":"2023 Aug 17. doi: 10.3324\/haematol.2023.283863. Online ahead of print.","author":"Griffin M, Eikema DJ, Verheggen I, Kulagin A, Tjon JM, Fattizzo B, Ingram W, Zaidi U, Desnica L, Giammarco S, Drozd-Sokolowska J, Xicoy B, Patriarca A, Loschi M, Szmigielska-Kaplon A, Beier F, Cignetti A, Drexler B, Gavriilaki E, Lanza F, Orvain C, Risitano AM, De la Camara R, De Latour RP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37584297"},{"title01":"Double filtration plasmapheresis combined with rituximab for donor-specific antibody desensitization in haploidentical haematopoietic stem cell transplantation","title02":"Double filtration plasmapheresis combined with rituximab for donor-specific antibody desensitization in haploidentical haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"2023 Aug 24. doi: 10.1111\/bjh.19046. Online ahead of print.","author":"Liu L, Ji X, Zhu P, Yang L, Shi J, Zhao Y, Lai X, Yu J, Fu H, Ye Y, Wu Y, Ying J, Huang H, Luo Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37621146"},{"title01":"Impact of GVHD on lymphoma progression: Nationwide study from Japanese Society for Transplantation and Cellular Therapy","title02":"Impact of GVHD on lymphoma progression: Nationwide study from Japanese Society for Transplantation and Cellular Therapy","journal":"Br J Haematol","issue":"2023 Aug 23. doi: 10.1111\/bjh.19041. Online ahead of print.","author":"Watanabe M, Kanda J, Fukuda T, Uchida N, Ikegame K, Kataoka K, Kobayashi H, Ara T, Ishikawa J, Matsuoka KI, Sugio Y, Nakazawa H, Ikeda T, Atsuta Y, Kondo E, Suzuki R; Japanese Society for Transplantation and Cellular Therapy, Adult Lymphoma Working Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37614023"},{"title01":"The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation","title02":"The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation","journal":"Br J Haematol","issue":"2023 Aug 24. doi: 10.1111\/bjh.19055. Online ahead of print.","author":"Elias S, Brown S, Devlin SM, Barker JN, Cho C, Chung DJ, Dahi PB, Giralt S, Gyurkocza B, Jakubowski AA, Lahoud OB, Landau H, Lin RJ, Papadopoulos EB, Politikos I, Ponce DM, Scordo M, Shaffer BC, Shah GL, Tamari R, Young JW, Perales MA, Shouval R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37614192"},{"title01":"ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non-myeloablative conditioning","title02":"ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non-myeloablative conditioning","journal":"Br J Haematol","issue":"2023 Aug 10. doi: 10.1111\/bjh.19031. Online ahead of print.","author":"Aydin M, de Leeuw DC, Rutten CE, Visser OJ, Tang MW, van Roessel C, Janssen JJW, Biemond BJ, van de Loosdrecht AA, Hazenberg MD, Meijer E, Nur E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37565363"},{"title01":"How to optimize outcome of patients undergoing HLA-matched related haematopoietic stem cell transplantation in acquired and inherited bone marrow failure syndromes","title02":"How to optimize outcome of patients undergoing HLA-matched related haematopoietic stem cell transplantation in acquired and inherited bone marrow failure syndromes","journal":"Br J Haematol","issue":"2023 Aug 16. doi: 10.1111\/bjh.19047. Online ahead of print.","author":"Giardino S, Pierri F, Faraci M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37583352"},{"title01":"GVHD: better safe than sorry","title02":"GVHD: better safe than sorry","journal":"Blood","issue":"2023 Aug 24;142(8):680-682.","author":"Bonifazi F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37616024"},{"title01":"How I treat transplant-eligible patients with myelofibrosis","title02":"How I treat transplant-eligible patients with myelofibrosis","journal":"Blood","issue":"2023 Aug 30:blood.2023021218. doi: 10.1182\/blood.2023021218. Online ahead of print.","author":"Kr\u00f6ger N, Wolschke C, Gagelmann N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37647853"},{"title01":"Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation","title02":"Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation","journal":"Leukemia","issue":"2023 Aug 11. doi: 10.1038\/s41375-023-01998-7. Online ahead of print.","author":"N\u00f8rgaard JN, Abildgaard N, Lys\u00e9n A, Tsykunova G, Vangsted AJ, Jo\u00e3o C, Remen N, Nielsen LK, Osnes L, Stokke C, Connelly JP, Revheim MR; Nordic Myeloma Study Group (NMSG); Schjesvold F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37568010"},{"title01":"Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study","title02":"Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study","journal":"J Clin Oncol","issue":"2023 Aug 22:JCO2300866. doi: 10.1200\/JCO.23.00866. Online ahead of print.","author":"Versluis J, Saber W, Tsai HK, Gibson CJ, Dillon LW, Mishra A, McGuirk J, Maziarz RT, Westervelt P, Hegde P, Mukherjee D, Martens MJ, Logan B, Horowitz M, Hourigan CS, Nakamura R, Cutler C, Lindsley RC; Blood and Marrow Transplant Clinical Trials Network.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37607457"},{"title01":"Which is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome?","title02":"Which is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome?","journal":"Haematologica","issue":"2023 Aug 31. doi: 10.3324\/haematol.2023.283719. Online ahead of print.","author":"Autore F, Bramanti S, Lessi F, Innocenti I, Galli E, Rocchi S, Ribolla R, Derudas D, Oliva S, Stefanoni P, Marcatti M, Schenone A, La Nasa G, Crippa C, Zamagni E, Riva M, Mazza R, Mannina D, Sica S, Bacigalupo A, Laurenti L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646655"},{"title01":"Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study","title02":"Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study","journal":"Haematologica","issue":"2023 Aug 31. doi: 10.3324\/haematol.2023.283175. Online ahead of print.","author":"Weller JF, Lengerke C, Finke J, Schetelig J, Platzbecker U, Einsele H, Schroeder T, Faul C, Stelljes M, Dreger P, Blau IW, Wulf G, Tischer J, Scheid C, Elmaagacli A, Neidlinger H, Flossdorf S, Bornh\u00e4user M, Bethge W, Fleischhauer K, Kr\u00f6ger N, De Wreede LC, Christopeit M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646665"},{"title01":"miR-30e-5p regulates leukemia stem cell self-renewal through the Cyb561\/ROS signaling pathway","title02":"miR-30e-5p regulates leukemia stem cell self-renewal through the Cyb561\/ROS signaling pathway","journal":"Haematologica","issue":"2023 Aug 17. doi: 10.3324\/haematol.2023.282837. Online ahead of print.","author":"Ge Y, Hong M, Zhang Y, Wang J, Li L, Zhu H, Sheng Y, Wu WS, Zhang Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37584287"},{"title01":"Double filtration plasmapheresis combined with rituximab for donor-specific antibody desensitization in haploidentical haematopoietic stem cell transplantation","title02":"Double filtration plasmapheresis combined with rituximab for donor-specific antibody desensitization in haploidentical haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"2023 Aug 24. doi: 10.1111\/bjh.19046. Online ahead of print.","author":"Liu L, Ji X, Zhu P, Yang L, Shi J, Zhao Y, Lai X, Yu J, Fu H, Ye Y, Wu Y, Ying J, Huang H, Luo Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37621146"},{"title01":"The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation","title02":"The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation","journal":"Br J Haematol","issue":"2023 Aug 24. doi: 10.1111\/bjh.19055. Online ahead of print.","author":"Elias S, Brown S, Devlin SM, Barker JN, Cho C, Chung DJ, Dahi PB, Giralt S, Gyurkocza B, Jakubowski AA, Lahoud OB, Landau H, Lin RJ, Papadopoulos EB, Politikos I, Ponce DM, Scordo M, Shaffer BC, Shah GL, Tamari R, Young JW, Perales MA, Shouval R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37614192"},{"title01":"ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non-myeloablative conditioning","title02":"ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non-myeloablative conditioning","journal":"Br J Haematol","issue":"2023 Aug 10. doi: 10.1111\/bjh.19031. Online ahead of print.","author":"Aydin M, de Leeuw DC, Rutten CE, Visser OJ, Tang MW, van Roessel C, Janssen JJW, Biemond BJ, van de Loosdrecht AA, Hazenberg MD, Meijer E, Nur E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37565363"},{"title01":"How to optimize outcome of patients undergoing HLA-matched related haematopoietic stem cell transplantation in acquired and inherited bone marrow failure syndromes","title02":"How to optimize outcome of patients undergoing HLA-matched related haematopoietic stem cell transplantation in acquired and inherited bone marrow failure syndromes","journal":"Br J Haematol","issue":"2023 Aug 16. doi: 10.1111\/bjh.19047. Online ahead of print.","author":"Giardino S, Pierri F, Faraci M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37583352"},{"title01":"PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy","title02":"PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy","journal":"Blood","issue":"2023 Aug 18:blood.2023020331. doi: 10.1182\/blood.2023020331. Online ahead of print.","author":"Miller PG, Sperling AS, Mayerhofer C, McConkey M, Ellegast JM, Da Silva C, Cohen DN, Wang C, Sharda A, Yan N, Saha S, Schluter C, Schechter IA, S\u0142abicki M, Sandoval B, Kahn J, Boettcher S, Gibson CJ, Scadden DT, Stegmaier K, Bhatt S, Lindsley RC, Ebert BL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37595362"},{"title01":"Introduction to a review series on hematopoietic stem cells","title02":"Introduction to a review series on hematopoietic stem cells","journal":"Blood","issue":"2023 Aug 10;142(6):497.","author":"Crispino JD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37561539"},{"title01":"Loss of endothelial membrane KIT Ligand affects systemic KIT ligand levels but not bone marrow hematopoietic stem cells","title02":"Loss of endothelial membrane KIT Ligand affects systemic KIT ligand levels but not bone marrow hematopoietic stem cells","journal":"Blood","issue":"2023 Aug 10:blood.2022019018. doi: 10.1182\/blood.2022019018. Online ahead of print.","author":"Matsuoka S, Facchini R, Luis TC, Carrelha J, Woll PS, Mizukami T, Wu B, Boukarabila H, Buono M, Norfo R, Arai F, Suda T, Mead A, Nerlov C, Jacobsen SEW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37562000"},{"title01":"Genotype, Oxidase Status, and Preceding Infection or Autoinflammation Do Not Affect Allogeneic HCT Outcomes for CGD","title02":"Genotype, Oxidase Status, and Preceding Infection or Autoinflammation Do Not Affect Allogeneic HCT Outcomes for CGD","journal":"Blood","issue":"2023 Aug 10:blood.2022019586. doi: 10.1182\/blood.2022019586. Online ahead of print.","author":"Leiding JW, Arnold DE, Parikh SH, Logan BR, Marsh RA, Griffith LM, Wu R, Kidd S, Mallhi KK, Chellapandian D, Si Lim S, Grunebaum E, Falcone EL, Murguia-Favela L, Grossman D, Prasad VK, Heimall JR, Touzot F, Burroughs L, Bleesing J, Kapoor N, Dara J, Williams O, Kapadia M, Oshrine BR, Bednarski JJ, Rayes A, Chong H, Cuvelier GDE, Forbes Satter LR, Martinez C, Vander Lugt MT, Yu LC, Chandrakasan S, Joshi A, Prockop SE, D\u00e1vila Salda\u00f1a BJ, Aquino V, Broglie L, Ebens CL, Madden LM, DeSantes K, Milner J, Rangarajan HG, Shah A, Gilio AP, Knutsen AP, Miller HK, Moore TB, Graham P, Bauchat A, Bunin NJ, Teira P, Petrovic A, Chandra S, Abdel-Azim H, Dorsey M, Birbrayer O, Cowan MJ, Dvorak CC, Haddad E, Kohn DB, Notarangelo LD, Pai SY, Puck JM, Pulsipher MA, Torgerson TR, Malech HL, Kang EM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37562003"},{"title01":"LepR+ niche cell-derived AREG compromises hematopoietic stem cell maintenance under conditions of DNA repair deficiency and aging","title02":"LepR+ niche cell-derived AREG compromises hematopoietic stem cell maintenance under conditions of DNA repair deficiency and aging","journal":"Blood","issue":"2023 Aug 15:blood.2022018212. doi: 10.1182\/blood.2022018212. Online ahead of print.","author":"Wu L, Lin Q, Chatla S, Amarachintha SP, Wilson AF, Atale N, Gao ZJ, Joseph J, Wolff E, Du W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37584437"},{"title01":"SARS-CoV-2 vaccination in 361 non-transplanted patients with aplastic anemia and\/or paroxysmal nocturnal hemoglobinuria","title02":"SARS-CoV-2 vaccination in 361 non-transplanted patients with aplastic anemia and\/or paroxysmal nocturnal hemoglobinuria","journal":"Haematologica","issue":"2023 Aug 17. doi: 10.3324\/haematol.2023.283863. Online ahead of print.","author":"Griffin M, Eikema DJ, Verheggen I, Kulagin A, Tjon JM, Fattizzo B, Ingram W, Zaidi U, Desnica L, Giammarco S, Drozd-Sokolowska J, Xicoy B, Patriarca A, Loschi M, Szmigielska-Kaplon A, Beier F, Cignetti A, Drexler B, Gavriilaki E, Lanza F, Orvain C, Risitano AM, De la Camara R, De Latour RP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37584297"},{"title01":"Neurofilament light chain: A potential biomarker for cerebrovascular disease in children with sickle cell anaemia","title02":"Neurofilament light chain: A potential biomarker for cerebrovascular disease in children with sickle cell anaemia","journal":"Br J Haematol","issue":"2023 Aug 15. doi: 10.1111\/bjh.19036. Online ahead of print.","author":"Green NS, Rosano C, Bangirana P, Opoka R, Munube D, Kasirye P, Kawooya M, Lubowa SK, Mupere E, Conroy A, Minja FJ, Boehme AK, Kang MS, Honig LS, Idro R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37581299"},{"title01":"Bone marrow failure on steroids: when to use androgens?","title02":"Bone marrow failure on steroids: when to use androgens?","journal":"Haematologica","issue":"2023 Aug 17:0. doi: 10.3324\/haematol.2023.283564. Online ahead of print.","author":"Calado RT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37584294"},{"title01":"A novel mutation in MECOM affects MPL regulation in vitro and results in thrombocytopenia and bone marrow failure","title02":"A novel mutation in MECOM affects MPL regulation in vitro and results in thrombocytopenia and bone marrow failure","journal":"Br J Haematol","issue":"2023 Aug 23. doi: 10.1111\/bjh.19023. Online ahead of print.","author":"Ammeti D, Marzollo A, Gabelli M, Zanchetta ME, Tretti-Parenzan C, Bottega R, Capaci V, Biffi A, Savoia A, Bresolin S, Faleschini M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37610030"},{"title01":"How to optimize outcome of patients undergoing HLA-matched related haematopoietic stem cell transplantation in acquired and inherited bone marrow failure syndromes","title02":"How to optimize outcome of patients undergoing HLA-matched related haematopoietic stem cell transplantation in acquired and inherited bone marrow failure syndromes","journal":"Br J Haematol","issue":"2023 Aug 16. doi: 10.1111\/bjh.19047. Online ahead of print.","author":"Giardino S, Pierri F, Faraci M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37583352"},{"title01":"Management of Primary Immune Thrombocytopenia in Pregnancy","title02":"Management of Primary Immune Thrombocytopenia in Pregnancy","journal":"N Engl J Med","issue":"2023 Aug 10;389(6):540-548.","author":"Bussel JB, Hou M, Cines DB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37590449"},{"title01":"A proposal for new definition (s) and management approach to paediatric refractory ITP: Reflections from the Intercontinental ITP Study Group","title02":"A proposal for new definition (s) and management approach to paediatric refractory ITP: Reflections from the Intercontinental ITP Study Group","journal":"Br J Haematol","issue":"2023 Aug 29. doi: 10.1111\/bjh.19072. Online ahead of print.","author":"Neunert C, Heitink-Polle KMJ, Lambert MP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37641973"},{"title01":"Refractory immune thrombocytopenia in adults: Towards a new definition","title02":"Refractory immune thrombocytopenia in adults: Towards a new definition","journal":"Br J Haematol","issue":"2023 Aug 29. doi: 10.1111\/bjh.19075. Online ahead of print.","author":"Arnold DM, Clerici B, Ilicheva E, Ghanima W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37642211"},{"title01":"Intramuscular anti-D treatment for immune thrombocytopenia-Response","title02":"Intramuscular anti-D treatment for immune thrombocytopenia-Response","journal":"Br J Haematol","issue":"2023 Aug 29. doi: 10.1111\/bjh.19065. Online ahead of print.","author":"Bussel JB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37644644"},{"title01":"Clinical significance of antinuclear antibodies in primary immune thrombocytopenia","title02":"Clinical significance of antinuclear antibodies in primary immune thrombocytopenia","journal":"Br J Haematol","issue":"2023 Aug 30. doi: 10.1111\/bjh.19069. Online ahead of print.","author":"Moulis G, Aladjidi N, Godeau B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646171"},{"title01":"Transient increase in platelet counts associated with COVID-19 infection during TPO-RA as the second-line treatment in children with ITP","title02":"Transient increase in platelet counts associated with COVID-19 infection during TPO-RA as the second-line treatment in children with ITP","journal":"Br J Haematol","issue":"2023 Aug 23. doi: 10.1111\/bjh.19040. Online ahead of print.","author":"Wang Z, Cheng X, Wang N, Meng J, Ma J, Chen Z, Wu R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37609794"},{"title01":"S1P-S1PR3-RAS promotes the progression of S1PR3(hi) TAL1(+) T-cell acute lymphoblastic leukemia that can be effectively inhibited by an S1PR3 antagonist","title02":"S1P-S1PR3-RAS promotes the progression of S1PR3(hi) TAL1(+) T-cell acute lymphoblastic leukemia that can be effectively inhibited by an S1PR3 antagonist","journal":"Leukemia","issue":"2023 Aug 17. doi: 10.1038\/s41375-023-02000-0. Online ahead of print.","author":"Zhu D, Jiang T, Ma D, Zhang H, Zhang J, Lv W, Gong M, Wang H, Liu Z, Su H, Zeng L, Liu S, Tang S, Yang B, Tshavuka FI, Fu G, Liu Z, Peng D, Liu H, Yan Z, Cao Z, Zhao H, He TC, Yu J, Shu Y, Zou L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37591940"},{"title01":"Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients","title02":"Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients","journal":"Leukemia","issue":"2023 Aug 17. doi: 10.1038\/s41375-023-01999-6. Online ahead of print.","author":"Jahn E, Saadati M, Fenaux P, Gobbi M, Roboz GJ, Bullinger L, Lutsik P, Riedel A, Plass C, Jahn N, Walter C, Holzmann K, Hao Y, Naim S, Schreck N, Krzykalla J, Benner A, Keer HN, Azab M, D\u00f6hner K, D\u00f6hner H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37591941"},{"title01":"TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia","title02":"TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia","journal":"Leukemia","issue":"2023 Aug 17. doi: 10.1038\/s41375-023-01993-y. Online ahead of print.","author":"Tan SH, Tan TK, Yokomori R, Liao M, Huang XZ, Yeoh AEJ, Sanda T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37591943"},{"title01":"Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial","title02":"Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial","journal":"Leukemia","issue":"2023 Aug 21. doi: 10.1038\/s41375-023-02001-z. Online ahead of print.","author":"Sekeres MA, Montesinos P, Novak J, Wang J, Jeyakumar D, Tomlinson B, Mayer J, Jou E, Robak T, Taussig DC, Dombret H, Merchant A, Shaik N, O'Brien T, Roh W, Liu X, Ma W, DiRienzo CG, Chan G, Cortes JE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37604981"},{"title01":"Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS\/AML overlap patients defined by ICC","title02":"Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS\/AML overlap patients defined by ICC","journal":"Leukemia","issue":"2023 Aug 12. doi: 10.1038\/s41375-023-02004-w. Online ahead of print.","author":"Huber S, Baer C, Hutter S, Dicker F, Fuhrmann I, Meggendorfer M, Pohlkamp C, Kern W, Haferlach T, Haferlach C, Hoermann G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37573403"},{"title01":"Perspectives on acute myeloid leukemia diagnosis: a comparative analysis of the latest World Health Organization and the International Consensus Classifications","title02":"Perspectives on acute myeloid leukemia diagnosis: a comparative analysis of the latest World Health Organization and the International Consensus Classifications","journal":"Leukemia","issue":"2023 Aug 14. doi: 10.1038\/s41375-023-01996-9. Online ahead of print.","author":"Jung J, Kwag D, Kim Y, Lee JM, Ahn A, Kim HS, Bae B, Park S, Kim HJ, Cho BS, Kim M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37580414"},{"title01":"Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia","title02":"Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia","journal":"Leukemia","issue":"2023 Aug 16. doi: 10.1038\/s41375-023-02005-9. Online ahead of print.","author":"Eifert T, Hsu CJ, Becker AL, Graessle S, Horne A, Bemmann F, Zhang Q, Heuser M, Vasioukhin V, Scholl S, Hochhaus A, Siegerist F, Endlich N, Bullinger L, Lane SW, Haas S, Schnoeder TM, Heidel FH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37587260"},{"title01":"Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures","title02":"Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures","journal":"Lancet Haematol","issue":"2023 Aug 18:S2352-3026(23)00173-4. doi: 10.1016\/S2352-3026(23)00173-4. Online ahead of print.","author":"Smit Y, Metsemakers SJJPM, Janssen JJWM, Posthuma EFM, Walraven I, Hermens RPMG, Blijlevens NMA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37604177"},{"title01":"Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts","title02":"Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts","journal":"Lancet Haematol","issue":"2023 Sep;10(9):e767-e776.","author":"Shallis RM, Daver N, Altman JK, Komrokji RS, Pollyea DA, Badar T, Bewersdorf JP, Bhatt VR, de Botton S, de la Fuente Burguera A, Carraway HE, Desai P, Dillon R, Duployez N, El Chaer F, Fathi AT, Freeman SD, Gojo I, Grunwald MR, Jonas BA, Konopleva M, Lin TL, Mannis GN, Mascarenhas J, Michaelis LC, Mims AS, Montesinos P, Pozdnyakova O, Pratz KW, Schuh AC, Sekeres MA, Smith CC, Stahl M, Subklewe M, Uy GL, Voso MT, Walter RB, Wang ES, Zeidner JF, \u017du\u010denka A, Zeidan AM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37572683"},{"title01":"Embracing chimeric antigen receptors for relapsed chronic lymphocytic leukaemia","title02":"Embracing chimeric antigen receptors for relapsed chronic lymphocytic leukaemia","journal":"Lancet","issue":"2023 Aug 19;402(10402):590-592.","author":"Kamdar M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37597880"},{"title01":"What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?","title02":"What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?","journal":"J Clin Oncol","issue":"2023 Aug 23:JCO2202868. doi: 10.1200\/JCO.22.02868. Online ahead of print.","author":"DeWolf S, Tallman MS, Rowe JM, Salman MY.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37611216"},{"title01":"Thiostrepton induces cell death of acute myeloid leukemia blasts and the associated macrophage population","title02":"Thiostrepton induces cell death of acute myeloid leukemia blasts and the associated macrophage population","journal":"Haematologica","issue":"2023 Aug 31. doi: 10.3324\/haematol.2023.283621. Online ahead of print.","author":"Weinh\u00e4user I, Pereira-Martins DA, Hilberink JR, Brouwers-Vos A, Rego EM, Huls G, Schuringa JJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646656"},{"title01":"Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia","title02":"Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia","journal":"Haematologica","issue":"2023 Aug 31. doi: 10.3324\/haematol.2023.282894. Online ahead of print.","author":"Ingelman-Sundberg HM, Blixt L, Wullimann D, Wu J, Gao Y, Healy K, Muschiol S, Bogdanovic G, \u00c5berg M, Kjellander C, Grifoni A, Sette A, Aleman S, Chen P, Blennow O, Hansson L, Ljunggren HG, Chen MS, Buggert M, \u00d6sterborg A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646668"},{"title01":"Global miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations","title02":"Global miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations","journal":"Haematologica","issue":"2023 Aug 31. doi: 10.3324\/haematol.2023.283181. Online ahead of print.","author":"Liu P, Wang K, Li J, Ogasawara MA, Xia Z, Wierda WG, Keating MJ, Li Y, Huang P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646669"},{"title01":"Distinct t(14;19) translocation patterns in atypical chronic lymphocytic leukemia and marginal zone lymphomas","title02":"Distinct t(14;19) translocation patterns in atypical chronic lymphocytic leukemia and marginal zone lymphomas","journal":"Haematologica","issue":"2023 Aug 24. doi: 10.3324\/haematol.2023.283975. Online ahead of print.","author":"K\u00fcppers R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37608774"},{"title01":"Vacuolated lymphocytes as initial presentation of angioimmunoblastic T-cell lymphoma","title02":"Vacuolated lymphocytes as initial presentation of angioimmunoblastic T-cell lymphoma","journal":"Br J Haematol","issue":"2023 Aug 23. doi: 10.1111\/bjh.19030. Online ahead of print.","author":"Gauthier M, Dombrowski D, Vergnolle I, Kfoury E, Vergez F, Daniau B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37614039"},{"title01":"Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement","title02":"Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement","journal":"Br J Haematol","issue":"2023 Aug 16. doi: 10.1111\/bjh.19037. Online ahead of print.","author":"Ryan CE, Zon RL, Redd R, Fisher DC, Shouval R, Kumar A, Crombie JL, Sadrzadeh H, Kim AI, Nayak L, Chukwueke UN, Jacobson CA, Frigault MJ, Palomba ML, Armand P, Epstein-Peterson Z, Merryman RW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37584155"},{"title01":"ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells","title02":"ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells","journal":"Br J Haematol","issue":"2023 Aug 16. doi: 10.1111\/bjh.19018. Online ahead of print.","author":"Chung EYL, Sartori G, Ponzoni M, Cascione L, Priebe V, Xu-Monette ZY, Fang X, Zhang M, Visco C, Tzankov A, Rinaldi A, Sgrignani J, Zucca E, Rossi D, Cavalli A, Inghirami G, Scott DW, Young KH, Bertoni F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37584198"},{"title01":"Oncogene-induced MALT1 protease activity drives post-transcriptional gene expression in malignant lymphomas","title02":"Oncogene-induced MALT1 protease activity drives post-transcriptional gene expression in malignant lymphomas","journal":"Blood","issue":"2023 Aug 25:blood.2023021299. doi: 10.1182\/blood.2023021299. Online ahead of print.","author":"Wimberger N, Ober F, Avar G, Grau M, Xu W, Lenz G, Menden MP, Krappmann D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37623434"},{"title01":"A novel case of peripheral T-cell lymphoma, not otherwise specified, with rhabdoid morphology and INI1 loss","title02":"A novel case of peripheral T-cell lymphoma, not otherwise specified, with rhabdoid morphology and INI1 loss","journal":"Blood","issue":"2023 Aug 17;142(7):675.","author":"Saksena A, Rajgariah A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37590025"},{"title01":"Follicular lymphoma involving the synovium in\u00a0rheumatoid arthritis","title02":"Follicular lymphoma involving the synovium in\u00a0rheumatoid arthritis","journal":"Blood","issue":"2023 Aug 10;142(6):611.","author":"Ding Y, Jaffe ES.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37561538"},{"title01":"An AID to follicular lymphoma transformation","title02":"An AID to follicular lymphoma transformation","journal":"Blood","issue":"2023 Aug 10;142(6):500-502.","author":"Phelan JD, Jaffe ES.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37561540"},{"title01":"CARD11 gain of function upregulates BCL2A1 and promotes resistance to targeted therapies combination in B-cell lymphoma","title02":"CARD11 gain of function upregulates BCL2A1 and promotes resistance to targeted therapies combination in B-cell lymphoma","journal":"Blood","issue":"2023 Aug 10:blood.2023020211. doi: 10.1182\/blood.2023020211. Online ahead of print.","author":"Decombis S, Bellanger C, Le Bris Y, Madiot C, Jardine J, Santos JC, Boulet D, Dousset C, Menard A, Kervoelen C, Douillard E, Moreau P, Minvielle S, Moreau-Aubry A, Tessoulin B, Roue G, Bid\u00e8re N, Le Gouill S, Pellat-Deceunynck C, Chiron D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37562004"},{"title01":"Mezigdomide and Multiple Myeloma","title02":"Mezigdomide and Multiple Myeloma","journal":"N Engl J Med","issue":"2023 Aug 30. doi: 10.1056\/NEJMe2307370. Online ahead of print.","author":"Shortt J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646699"},{"title01":"Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma","title02":"Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma","journal":"N Engl J Med","issue":"2023 Aug 30. doi: 10.1056\/NEJMoa2303194. Online ahead of print.","author":"Richardson PG, Trudel S, Popat R, Mateos MV, Vangsted AJ, Ramasamy K, Martinez-Lopez J, Quach H, Orlowski RZ, Arnao M, Lonial S, Karanes C, Pawlyn C, Kim K, Oriol A, Berdeja JG, Rodr\u00edguez Otero P, Casas-Avil\u00e9s I, Spirli A, Poon J, Li S, Gong J, Wong L, Lamba M, Pierce DW, Amatangelo M, Peluso T, Maciag P, Katz J, Pourdehnad M, Bahlis NJ; CC-92480-MM-001 Study Investigators.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646702"},{"title01":"Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation","title02":"Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation","journal":"Leukemia","issue":"2023 Aug 11. doi: 10.1038\/s41375-023-01998-7. Online ahead of print.","author":"N\u00f8rgaard JN, Abildgaard N, Lys\u00e9n A, Tsykunova G, Vangsted AJ, Jo\u00e3o C, Remen N, Nielsen LK, Osnes L, Stokke C, Connelly JP, Revheim MR; Nordic Myeloma Study Group (NMSG); Schjesvold F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37568010"},{"title01":"ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed\/refractory multiple myeloma-final results of a phase I\/IIa study","title02":"ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed\/refractory multiple myeloma-final results of a phase I\/IIa study","journal":"Haematologica","issue":"Haematologica. 2023 Aug 31. doi: 10.3324\/haematol.2023.283490. Online ahead of print.","author":"Ocio EM, Efebera YA, H\u00e1jek R, Straub J, Maisnar V, Eveillard JR, Karlin L, Mateos MV, Oriol A, Ribrag V, Richardson PG, Norin S, Oberm\u00fcller J, Bakker NA, Pour L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646657"},{"title01":"The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma","title02":"The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma","journal":"Haematologica","issue":"Haematologica. 2023 Aug 31. doi: 10.3324\/haematol.2023.283590. Online ahead of print.","author":"Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37646658"},{"title01":"A Case of Fetal-Induced Graft-versus-Host Disease","title02":"A Case of Fetal-Induced Graft-versus-Host Disease","journal":"N Engl J Med","issue":"2023 Aug 17;389(7):668-670.","author":"Schreiber AR, Santos J, McMahon B, Buckner TW, Olson C, Alberti MO, Guimar\u00e3es-Young A, Knoeckel C, Broussard L, Aubrey M, Palmer BE, Weiss E, Connors GR, Brunner S, Wisell JA, Pacheco T, Aisner DL, Gutman JA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37585636"},{"title01":"FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML","title02":"<i>FLT3<\/i> inhibitors as MRD-guided salvage treatment for molecular failure in <i>FLT3<\/i> mutated AML","journal":"Leukemia","issue":"2023 Aug 9. doi: 10.1038\/s41375-023-01994-x. Online ahead of print.","author":"Othman J, Potter N, Mokretar K, Taussig D, Khan A, Krishnamurthy P, Latif AL, Cahalin P, Aries J, Amer M, Belsham E, Conneally E, Craddock C, Culligan D, Dennis M, Duncan C, Freeman SD, Furness C, Gilkes A, Gkreka P, Hodgson K, Ingram W, Jain M, King A, Knapper S, Kottaridis P, McMullin MF, Mohite U, Ngu L, O'Nions J, Patrick K, Rider T, Roberts W, Severinsen MT, Storrar N, Taylor T, Russell NH, Dillon R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37558736"},{"title01":"Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia","title02":"Optimising maintenance therapy after transplantation: sorafenib's role in patients with <i>FLT3<\/i>-ITD acute myeloid leukaemia","journal":"Lancet Haematol","issue":"2023 Aug;10(8):e559-e561.","author":"Yilmaz M, Daver N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37532412"},{"title01":"Power out chronic lymphocytic leukemia: unplugging OXPHOS\/mTOR pathways to overcome Venetoclax resistance","title02":"Power out chronic lymphocytic leukemia: unplugging OXPHOS\/mTOR pathways to overcome Venetoclax resistance","journal":"Haematologica","issue":"2023 Aug 3. doi: 10.3324\/haematol.2023.283847. Online ahead of print.","author":"Viry E, Paggetti J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37534496"},{"title01":"Is it time for age and clinical adjusted minimal residual disease in acute myeloid leukemia?","title02":"Is it time for age and clinical adjusted minimal residual disease in acute myeloid leukemia?","journal":"Haematologica","issue":"2023 Aug 3. doi: 10.3324\/haematol.2023.283693. Online ahead of print.","author":"Ofran Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37534509"},{"title01":"Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia","title02":"Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia","journal":"Haematologica","issue":"2023 Aug 3. doi: 10.3324\/haematol.2023.283520. Online ahead of print.","author":"Dillon LW, Higgins J, Nasif H, Othus M, Beppu L, Smith TH, Schmidt E, Valentine Iii CC, Salk JJ, Wood BL, Erba HP, Radich JP, Hourigan CS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37534515"},{"title01":"Molecular predictors of response and survival following IDH1\/2 inhibitor monotherapy in acute myeloid leukemia","title02":"Molecular predictors of response and survival following IDH1\/2 inhibitor monotherapy in acute myeloid leukemia","journal":"Haematologica","issue":"2023 Aug 3. doi: 10.3324\/haematol.2023.283732. Online ahead of print.","author":"Gangat N, McCullough K, Abdelmagid M, Karrar O, Powell M, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Saliba A, Torghabeh MH, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Badar T, Foran J, Palmer J, Sproat L, Yi CA, Tefferi A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37534525"},{"title01":"Validation of SIE\/SIES\/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax","title02":"Validation of SIE\/SIES\/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax","journal":"Br J Haematol","issue":"2023 Aug 2. doi: 10.1111\/bjh.19022. Online ahead of print.","author":"Apolito V, Arrigo G, Vasseur L, Olivi M, Perrone S, Giai V, Secreto C, Di Biase F, De Simone MC, Copia C, Gravetti A, Freilone R, Bruno B, Lanzarone G, Beggiato E, Frairia C, Audisio E, D'Ardia S, Ferrero D, Cerrano M, Ferrara F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37533098"},{"title01":"Karyotype and outcome in CLL","title02":"Karyotype and outcome in CLL","journal":"Blood","issue":"2023 Aug 3;142(5):402-404.","author":"Mulligan SP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37535371"},{"title01":"Auer rod-like inclusions in chronic lymphocytic leukemia","title02":"Auer rod-like inclusions in chronic lymphocytic leukemia","journal":"Blood","issue":"2023 Jul 27;142(4):397.","author":"Morgan KM, Sojitra P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37498583"},{"title01":"ZDHHC21: a mitochondrial vulnerability in AML","title02":"ZDHHC21: a mitochondrial vulnerability in AML","journal":"Blood","issue":"2023 Jul 27;142(4):309-311.","author":"Schimmer AD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37498585"},{"title01":"Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosis","title02":"Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosis","journal":"Blood","issue":"2023 Jul 31:blood.2023019609. doi: 10.1182\/blood.2023019609. Online ahead of print.","author":"Kolijn PM, Sp\u00e4th F, Khouja M, Hengeveld PJ, Van Der Straten L, Darzentas N, Hultdin M, McKay J, Pott C, Vermeulen RCH, Langerak AW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37523714"},{"title01":"Optimising treatment of HIV-associated Hodgkin lymphoma","title02":"Optimising treatment of HIV-associated Hodgkin lymphoma","journal":"Lancet Haematol","issue":"2023 Aug;10(8):e563-e564.","author":"Hoffmann C, Hentrich M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37532413"},{"title01":"Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1\/2 trial","title02":"Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1\/2 trial","journal":"Lancet Haematol","issue":"2023 Aug;10(8):e624-e632.","author":"Rubinstein PG, Moore PC, Bimali M, Lee JY, Rudek MA, Chadburn A, Ratner L, Henry DH, Cesarman E, DeMarco CE, Costagliola D, Taoufik Y, Ramos JC, Sharon E, Reid EG, Ambinder RF, Mitsuyasu R, Mounier N, Besson C, Noy A; AIDS Malignancy Consortium; Lymphoma Study Association.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37532416"},{"title01":"ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma","title02":"ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma","journal":"J Clin Oncol","issue":"2023 Jul 28:101200JCO2300775. doi: 10.1200\/JCO.23.00775. Online ahead of print.","author":"Zinzani PL, Mayer J, Flowers CR, Bijou F, De Oliveira AC, Song Y, Zhang Q, Merli M, Bouabdallah K, Ganly P, Zhang H, Johnson R, Garc\u00eda-Sancho AM, Pulla MP, Trn\u011bn\u00fd M, Yuen S, Tilly H, Kingsley E, Tumyan G, Assouline SE, Auer R, Ivanova E, Kim P, Huang S, Delarue R, Trotman J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37506346"},{"title01":"Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial","title02":"Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial","journal":"Haematologica","issue":"2023 Aug 10. doi: 10.3324\/haematol.2023.283342. Online ahead of print.","author":"Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B, Cervera M, Luzardo H, Hernandez-Rivas JM, Sitges M, Garcia-Cadenas I, Abrisqueta P, Montesinos P, Bastos-Oreiro M, De Llano MQ, Bravo P, Torrent A, Herrera P, Garcia-Guinon A, Vall-Llovera F, Serrano J, Terol MJ, Bergua JM, Garcia-Noblejas A, Barrenetxea C, Llorente L, Garcia-Belmonte D, Gimeno E, Cladera A, Mercadal S, Sancho JM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37560813"},{"title01":"Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax","title02":"Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax","journal":"Haematologica","issue":"2023 Aug 3. doi: 10.3324\/haematol.2023.283245. Online ahead of print.","author":"Zhu F, Crombie JL, Ni W, Hoang NM, Garg S, Hackett L, Chong SJF, Collins MC, Rui L, Griffin J, Davids MS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37534528"},{"title01":"Rapid diagnosis and initiation of treatment has a crucial role in the prognosis of primary central nervous system lymphoma","title02":"Rapid diagnosis and initiation of treatment has a crucial role in the prognosis of primary central nervous system lymphoma","journal":"Br J Haematol","issue":"2023 Jul 31. doi: 10.1111\/bjh.19003. Online ahead of print.","author":"Kuitunen H, Puhakka I, R\u00f6nk\u00e4 A, Selander T, J\u00e4k\u00e4l\u00e4 P, Arkko UM, Klaavuniemi T, Sunela K, Rajam\u00e4ki A, Kuittinen O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37519227"},{"title01":"Bone marrow pseudo-Gaucher cells demonstrating haemophagocytosis associated with extranodal NK\/T cell lymphoma, nasal type","title02":"Bone marrow pseudo-Gaucher cells demonstrating haemophagocytosis associated with extranodal NK\/T cell lymphoma, nasal type","journal":"Br J Haematol","issue":"2023 Jul 31. doi: 10.1111\/bjh.18998. Online ahead of print.","author":"Jeffrey A, Mason G, Kerridge I, Kumar P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37525415"},{"title01":"Peripheral T-cell lymphoma with TFH phenotype and associated indolent T-lymphoblastic proliferation","title02":"Peripheral T-cell lymphoma with TFH phenotype and associated indolent T-lymphoblastic proliferation","journal":"Blood","issue":"2023 Aug 3;142(5):493.","author":"Symes E, Venkataraman G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37535366"},{"title01":"Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia","title02":"Optimising maintenance therapy after transplantation: sorafenib's role in patients with <i>FLT3<\/i>-ITD acute myeloid leukaemia","journal":"Lancet Haematol","issue":"2023 Aug;10(8):e559-e561.","author":"Yilmaz M, Daver N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37532412"},{"title01":"What role for somatic mutations in systemic inflammatory and autoimmune diseases associated with myelodysplastic neoplasms and chronic myelomonocytic leukemias?","title02":"What role for somatic mutations in systemic inflammatory and autoimmune diseases associated with myelodysplastic neoplasms and chronic myelomonocytic leukemias?","journal":"Leukemia","issue":"2023 Aug 4. doi: 10.1038\/s41375-023-01990-1. Online ahead of print.","author":"Zhao LP, Fenaux P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37542163"},{"title01":"A novel germline PAX5 single exon deletion in a pediatric patient with precursor B-cell leukemia","title02":"A novel germline PAX5 single exon deletion in a pediatric patient with precursor B-cell leukemia","journal":"Leukemia","issue":"2023 Aug 5. doi: 10.1038\/s41375-023-01991-0. Online ahead of print.","author":"van Engelen N, Roest M, van Dijk F, Sonneveld E, Bladergroen R, van Reijmersdal SV, van der Velden VHJ, Hoogeveen PG, Kors WA, Waanders E, Jongmans MCJ, Kuiper RP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37543654"},{"title01":"Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia","title02":"Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia","journal":"Leukemia","issue":"2023 Aug 5. doi: 10.1038\/s41375-023-01992-z. Online ahead of print.","author":"Hoshitsuki K, Zhou Y, Miller AM, Choi JK, Swanson HD, Bhakta NH, Jeha S, Karol SE, Ribeiro RC, Rubnitz JE, Mullighan CG, Cheng C, Yang JJ, Relling MV, Pui CH, Inaba H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37543655"},{"title01":"WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy","title02":"WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy","journal":"Leukemia","issue":"2023 Jul 28. doi: 10.1038\/s41375-023-01980-3. Online ahead of print.","author":"Fl\u00f8isand Y, Remberger M, Bigalke I, Josefsen D, V\u00e5lerhaugen H, Inderberg EM, Olaussen RW, Gjertsen BT, Goedkoop R, Geiger C, Prinz PU, Schnorfeil FM, Pinkernell K, Schendel DJ, Kvalheim G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37507426"},{"title01":"External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy","title02":"External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy","journal":"Leukemia","issue":"2023 Jul 29. doi: 10.1038\/s41375-023-01982-1. Online ahead of print.","author":"Qi F, Zhang X, Gale RP, Liu B, Huang J, Huang X, Jiang Q.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37516785"},{"title01":"Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification","title02":"Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification","journal":"Leukemia","issue":"2023 Jul 31. doi: 10.1038\/s41375-023-01985-y. Online ahead of print.","author":"Hochman MJ, Othus M, Hasserjian RP, Ambinder A, Brunner A, Percival MM, Hourigan CS, Swords R, DeZern AE, Estey EH, Karp JE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37524919"},{"title01":"Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms","title02":"Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms","journal":"Leukemia","issue":"2023 Jul 31. doi: 10.1038\/s41375-023-01981-2. Online ahead of print.","author":"Shih L, Othus M, Schonhoff K, Shaw C, Appelbaum J, Halpern AB, Becker PS, Walter RB, Estey E, Percival ME.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37524920"},{"title01":"XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression","title02":"XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression","journal":"Leukemia","issue":"2023 Aug 1. doi: 10.1038\/s41375-023-01984-z. Online ahead of print.","author":"Fisher JG, Doyle ADP, Graham LV, Sonar S, Sale B, Henderson I, Del Rio L, Johnson PWM, Landesman Y, Cragg MS, Forconi F, Walker CJ, Khakoo SI, Blunt MD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37528310"},{"title01":"Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study","title02":"Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study","journal":"J Clin Oncol","issue":"2023 Aug 2:JCO2202836. doi: 10.1200\/JCO.22.02836. Online ahead of print.","author":"Li J, Gao J, Liu A, Liu W, Xiong H, Liang C, Fang Y, Dai Y, Shao J, Yu H, Wang L, Wang L, Yang L, Yan M, Zhai X, Shi X, Tian X, Ju X, Chen Y, Wang J, Zhang L, Liang H, Chen S, Zhang J, Cao H, Jin J, Hu Q, Wang J, Wang Y, Zhou M, Han Y, Zhang R, Zhao W, Wang X, Lin L, Zhang R, Gao C, Xu L, Zhang Y, Fan J, Wu Y, Lin W, Yu J, Qi P, Huang P, Peng X, Peng Y, Wang T, Zheng H; Chinese Children's Leukemia Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37531592"},{"title01":"Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia","title02":"Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia","journal":"Haematologica","issue":"2023 Aug 10. doi: 10.3324\/haematol.2023.283723. Online ahead of print.","author":"Hantel A, Luskin MR, Khan I, Warner E, Patel AA, Walsh TP, DeAngelo DJ, Lathan CS, Abel GA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37560812"},{"title01":"Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial","title02":"Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial","journal":"Haematologica","issue":"2023 Aug 10. doi: 10.3324\/haematol.2023.283342. Online ahead of print.","author":"Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B, Cervera M, Luzardo H, Hernandez-Rivas JM, Sitges M, Garcia-Cadenas I, Abrisqueta P, Montesinos P, Bastos-Oreiro M, De Llano MQ, Bravo P, Torrent A, Herrera P, Garcia-Guinon A, Vall-Llovera F, Serrano J, Terol MJ, Bergua JM, Garcia-Noblejas A, Barrenetxea C, Llorente L, Garcia-Belmonte D, Gimeno E, Cladera A, Mercadal S, Sancho JM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37560813"},{"title01":"Chasing quality remission in acute myeloid leukemia: intensity of induction and residual disease","title02":"Chasing quality remission in acute myeloid leukemia: intensity of induction and residual disease","journal":"Haematologica","issue":"2023 Aug 1;108(8):1973-1974. doi: 10.3324\/haematol.2023.283541.","author":"Ofran Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37525958"},{"title01":"Phenotypic profiling of CD34+ cells by advanced flow cytometry improves diagnosis of Juvenile Myelomonocytic Leukemia","title02":"Phenotypic profiling of CD34+ cells by advanced flow cytometry improves diagnosis of Juvenile Myelomonocytic Leukemia","journal":"Haematologica","issue":"2023 Aug 3. doi: 10.3324\/haematol.2023.282805. Online ahead of print.","author":"Bugarin C, Antolini L, Buracchi C, Matarraz S, Coliva TA, Van der Velden VH, Szczepanski T, Da Costa ES, Van der Sluijs A, Novakova M, Mejstrikova E, Nierkens S, De Mello FV, Fernandez P, Aanei C, S\u0119dek \u0141, Strocchio L, Masetti R, Sainati L, Philipp\u00e9 J, Valsecchi MG, Locatelli F, Van Dongen JJM, Biondi A, Orfao A, Gaipa G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37534527"},{"title01":"Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?","title02":"Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?","journal":"Br J Haematol","issue":"2023 Aug 3. doi: 10.1111\/bjh.19013. Online ahead of print.","author":"Breccia M, Saglio G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37537862"},{"title01":"Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response","title02":"Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response","journal":"Br J Haematol","issue":"2023 Aug 4. doi: 10.1111\/bjh.19007. Online ahead of print.","author":"Apostolova P, Kreutmair S, Toffalori C, Punta M, Unger S, Burk AC, Wehr C, Maas-Bauer K, Melchinger W, Haring E, Hoefflin R, Shoumariyeh K, Hupfer V, Lauer EM, Duquesne S, Lowinus T, Gonzalo N\u00fa\u00f1ez N, Alberti C, da Costa Pereira S, Merten CH, Power L, Weiss M, B\u00f6ke C, Pfeifer D, Marks R, Bertz H, W\u00e4sch R, Ihorst G, Gentner B, Duyster J, Boerries M, Andrieux G, Finke J, Becher B, Vago L, Zeiser R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37539479"},{"title01":"FISH-ing for answers: Can genomic arrays add to our understanding of disease biology in low-risk chronic lymphocytic leukaemia?","title02":"FISH-ing for answers: Can genomic arrays add to our understanding of disease biology in low-risk chronic lymphocytic leukaemia?","journal":"Br J Haematol","issue":"2023 Jul 30. doi: 10.1111\/bjh.18992. Online ahead of print.","author":"Rhodes J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37519004"},{"title01":"Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling","title02":"Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling","journal":"Br J Haematol","issue":"2023 Jul 31. doi: 10.1111\/bjh.19008. Online ahead of print.","author":"Eadie LN, Rehn JA, Schutz CE, Heatley SL, Kutyna MM, Hiwase DK, White DL, Yeung DT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37519213"},{"title01":"Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia","title02":"Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia","journal":"Br J Haematol","issue":"2023 Jul 31. doi: 10.1111\/bjh.19012. Online ahead of print.","author":"Haddad FG, Kourie HR, Saleh K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37525325"},{"title01":"Convalescent plasma for patients with multiple myeloma and COVID-19; the European Myeloma Network consensus","title02":"Convalescent plasma for patients with multiple myeloma and COVID-19; the European Myeloma Network consensus","journal":"Leukemia","issue":"2023 Jul 28. doi: 10.1038\/s41375-023-01974-1. Online ahead of print.","author":"Terpos E, Musto P, Engelhardt M, Ntanasis-Stathopoulos I, Sonneveld P, Ludwig H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37507424"},{"title01":"EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma","title02":"EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma","journal":"Leukemia","issue":"2023 Aug 2. doi: 10.1038\/s41375-023-01983-0. Online ahead of print.","author":"Chemlal D, Varlet E, Machura A, Ovejero S, Requirand G, Robert N, Cartron G, Alaterre E, Bret C, Vincent L, Herbaux C, Cavalli G, Bruyer A, De Boussac H, Moreaux J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37532787"},{"title01":"Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma","title02":"Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma","journal":"Haematologica","issue":"2023 Aug 3. doi: 10.3324\/haematol.2023.283533. Online ahead of print.","author":"Cui J, Lv R, Yu T, Yan W, Xu J, Fan H, Li L, Liu Y, Du C, Deng S, Sui W, Xu Y, Yi S, Zou D, Qiu L, An G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37534514"},{"title01":"Direct oral anticoagulants versus aspirin for primary thromboprophylaxis in patients with multiple myeloma undergoing outpatient therapy: A systematic review and updated meta-analysis","title02":"Direct oral anticoagulants versus aspirin for primary thromboprophylaxis in patients with multiple myeloma undergoing outpatient therapy: A systematic review and updated meta-analysis","journal":"Br J Haematol","issue":"2023 Aug 2. doi: 10.1111\/bjh.19017. Online ahead of print.","author":"Costa TA, Felix N, Costa BA, Godoi A, Nogueira A, Rossi A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37533165"},{"title01":"LENALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT IXAZOMIB MAINTENANCE TAILORED BY RESIDUAL DISEASE STATUS IN MYELOMA","title02":"LENALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT IXAZOMIB MAINTENANCE TAILORED BY RESIDUAL DISEASE STATUS IN MYELOMA","journal":"Blood","issue":"2023 Jul 28:blood.2022019531. doi: 10.1182\/blood.2022019531. Online ahead of print.","author":"Rosi\u00f1ol L, Oriol A, R\u00edos-Tamayo R, Blanchard MJ, Jarque I, Bargay J, Hernandez Garcia MT, Caba\u00f1as V, Carrillo-Cruz E, Sureda A, Martinez-Lopez J, Krsnik I, Gonzalez ME, Casado Montero LF, Marti JM, Encinas C, de Arriba F, Palomera L, Sampol A, Gonzalez-Montes Y, Cabezudo E, Paiva B, Puig N, Cedena MT, de la Cruz J, Mateos MV, San-Miguel J, Lahuerta JJ, Blad\u00e9 J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37506339"},{"title01":"Patients receiving allogeneic haematopoietic stem-cell transplantation and clinical outcomes after early access to palliative care","title02":"Patients receiving allogeneic haematopoietic stem-cell transplantation and clinical outcomes after early access to palliative care","journal":"Lancet Haematol","issue":"2023 Jul 25:S2352-3026(23)00114-X. doi: 10.1016\/S2352-3026(23)00114-X. Online ahead of print.","author":"Sp\u00e4th C, Neumann T, Schmidt CA, Heidel FH, Kr\u00fcger WH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37506724"},{"title01":"UK liver transplantation allocation algorithm: transplant benefit score","title02":"UK liver transplantation allocation algorithm: transplant benefit score","journal":"Lancet","issue":"2023 Jul 29;402(10399):370-371.","author":"Prasad R, Hakeem AR, Menon K, Aluvihare V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37516539"},{"title01":"UK liver transplantation allocation algorithm: transplant benefit score","title02":"UK liver transplantation allocation algorithm: transplant benefit score","journal":"Lancet","issue":"2023 Jul 29;402(10399):371.","author":"Qu Z, Schmelzle M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37516541"},{"title01":"UK liver transplantation allocation algorithm: transplant benefit score &#8211; Authors&#8217; reply","title02":"UK liver transplantation allocation algorithm: transplant benefit score &#8211; Authors&#8217; reply","journal":"Lancet","issue":"2023 Jul 29;402(10399):371-372.","author":"Stutchfield BM, Attia A, Rowe IA, Harrison EM, Gordon-Walker T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37516542"},{"title01":"Impaired T-cell response to mRNA vaccination heralds risk of COVID-19 in long-term allogeneic hematopoietic stem cell transplantation survivors","title02":"Impaired T-cell response to mRNA vaccination heralds risk of COVID-19 in long-term allogeneic hematopoietic stem cell transplantation survivors","journal":"Haematologica","issue":"2023 Aug 3. doi: 10.3324\/haematol.2023.283551. Online ahead of print.","author":"Einarsdottir S, Waldenstr\u00f6m J, T\u00f6rnell A, Ringlander J, Stenb\u00e4ck JB, Malmstr\u00f6m S, Hellstrand K, Martner A, Lagging M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37534518"},{"title01":"Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response","title02":"Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response","journal":"Br J Haematol","issue":"2023 Aug 4. doi: 10.1111\/bjh.19007. Online ahead of print.","author":"Apostolova P, Kreutmair S, Toffalori C, Punta M, Unger S, Burk AC, Wehr C, Maas-Bauer K, Melchinger W, Haring E, Hoefflin R, Shoumariyeh K, Hupfer V, Lauer EM, Duquesne S, Lowinus T, Gonzalo N\u00fa\u00f1ez N, Alberti C, da Costa Pereira S, Merten CH, Power L, Weiss M, B\u00f6ke C, Pfeifer D, Marks R, Bertz H, W\u00e4sch R, Ihorst G, Gentner B, Duyster J, Boerries M, Andrieux G, Finke J, Becher B, Vago L, Zeiser R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37539479"},{"title01":"Pre-transplant and longitudinal changes in faecal microbiome characteristics are associated with subsequent development of chronic graft-versus-host disease","title02":"Pre-transplant and longitudinal changes in faecal microbiome characteristics are associated with subsequent development of chronic graft-versus-host disease","journal":"Br J Haematol","issue":"2023 Aug 8. doi: 10.1111\/bjh.19016. Online ahead of print.","author":"El Jurdi N, Holtan SG, Hoeschen A, Velguth J, Hillmann B, Betts BC, MacMillan ML, Weisdorf DJ, Khoruts A, Rashidi A, Shields-Cutler R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37553783"},{"title01":"Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling","title02":"Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling","journal":"Br J Haematol","issue":"2023 Jul 31. doi: 10.1111\/bjh.19008. Online ahead of print.","author":"Eadie LN, Rehn JA, Schutz CE, Heatley SL, Kutyna MM, Hiwase DK, White DL, Yeung DT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37519213"},{"title01":"How I Treat Post-Transplant Lymphoproliferative Disorder","title02":"How I Treat Post-Transplant Lymphoproliferative Disorder","journal":"Blood","issue":"2023 Aug 4:blood.2023020075. doi: 10.1182\/blood.2023020075. Online ahead of print.","author":"Amengual JE, Pro B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37540819"},{"title01":"Why are haematopoietic stem cells in the bone marrow: ontology recapitulates phylogeny","title02":"Why are haematopoietic stem cells in the bone marrow: ontology recapitulates phylogeny","journal":"Leukemia","issue":"2023 Jul 29. doi: 10.1038\/s41375-023-01986-x. Online ahead of print.","author":"Gale RP, Welsh J, Karam PA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37516786"},{"title01":"Patients receiving allogeneic haematopoietic stem-cell transplantation and clinical outcomes after early access to palliative care","title02":"Patients receiving allogeneic haematopoietic stem-cell transplantation and clinical outcomes after early access to palliative care","journal":"Lancet Haematol","issue":"2023 Jul 25:S2352-3026(23)00114-X. doi: 10.1016\/S2352-3026(23)00114-X. Online ahead of print.","author":"Sp\u00e4th C, Neumann T, Schmidt CA, Heidel FH, Kr\u00fcger WH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37506724"},{"title01":"Impaired T-cell response to mRNA vaccination heralds risk of COVID-19 in long-term allogeneic hematopoietic stem cell transplantation survivors","title02":"Impaired T-cell response to mRNA vaccination heralds risk of COVID-19 in long-term allogeneic hematopoietic stem cell transplantation survivors","journal":"Haematologica","issue":"2023 Aug 3. doi: 10.3324\/haematol.2023.283551. Online ahead of print.","author":"Einarsdottir S, Waldenstr\u00f6m J, T\u00f6rnell A, Ringlander J, Stenb\u00e4ck JB, Malmstr\u00f6m S, Hellstrand K, Martner A, Lagging M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37534518"},{"title01":"Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response","title02":"Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response","journal":"Br J Haematol","issue":"2023 Aug 4. doi: 10.1111\/bjh.19007. Online ahead of print.","author":"Apostolova P, Kreutmair S, Toffalori C, Punta M, Unger S, Burk AC, Wehr C, Maas-Bauer K, Melchinger W, Haring E, Hoefflin R, Shoumariyeh K, Hupfer V, Lauer EM, Duquesne S, Lowinus T, Gonzalo N\u00fa\u00f1ez N, Alberti C, da Costa Pereira S, Merten CH, Power L, Weiss M, B\u00f6ke C, Pfeifer D, Marks R, Bertz H, W\u00e4sch R, Ihorst G, Gentner B, Duyster J, Boerries M, Andrieux G, Finke J, Becher B, Vago L, Zeiser R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37539479"},{"title01":"Flipping the switch in the stem cell niche","title02":"Flipping the switch in the stem cell niche","journal":"Blood","issue":"2023 Aug 3;142(5):404-406.","author":"G\u00f6tze KS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37535369"},{"title01":"Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990-2021: findings from the Global Burden of Disease Study 2021","title02":"Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990-2021: findings from the Global Burden of Disease Study 2021","journal":"Lancet Haematol","issue":"2023 Jul 31:S2352-3026(23)00160-6. doi: 10.1016\/S2352-3026(23)00160-6. Online ahead of print.","author":"GBD 2021 Anaemia Collaborators.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37536353"},{"title01":"Measuring the global burden of anaemia","title02":"Measuring the global burden of anaemia","journal":"Lancet Haematol","issue":"2023 Jul 31:S2352-3026(23)00171-0. doi: 10.1016\/S2352-3026(23)00171-0. Online ahead of print.","author":"Pasricha SR, Moir-Meyer G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37536354"},{"title01":"The challenge of defining the global burden of iron deficiency anaemia","title02":"The challenge of defining the global burden of iron deficiency anaemia","journal":"Lancet Haematol","issue":"2023 Jul 31:S2352-3026(23)00168-0. doi: 10.1016\/S2352-3026(23)00168-0. Online ahead of print.","author":"Young MF, Luo H, Suchdev PS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37536355"},{"title01":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study","title02":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study","journal":"Lancet Haematol","issue":"2023 Jul 27:S2352-3026(23)00174-6. doi: 10.1016\/S2352-3026(23)00174-6. Online ahead of print.","author":"Gerds AT, Verstovsek S, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Oh S, Klencke BJ, Yu J, Donahue R, Kawashima J, Mesa R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37517413"},{"title01":"Regulatory T-cell dysfunctions are associated with increase in tumor necrosis factor \u03b1 in autoimmune hemolytic anemia and participate in Th17 polarization","title02":"Regulatory T-cell dysfunctions are associated with increase in tumor necrosis factor \u03b1 in autoimmune hemolytic anemia and participate in Th17 polarization","journal":"Haematologica","issue":"2023 Aug 3. doi: 10.3324\/haematol.2023.282859. Online ahead of print.","author":"Ciudad M, Ouandji S, Lamarth\u00e9e B, Cladi\u00e8re C, Ghesqui\u00e8re T, Nivet M, Th\u00e9bault M, Boidot R, Soudry-Faure A, Chevrier S, Richard C, Maillet T, Maurier F, Greigert H, Genet C, Ramon A, Trad M, Predan V, Saas P, Samson M, Bonnotte B, Audia S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37534543"},{"title01":"Ventricular arrhythmias in sickle cell anemia","title02":"Ventricular arrhythmias in sickle cell anemia","journal":"Blood","issue":"2023 Aug 3;142(5):399-400.","author":"Desai AA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37535367"},{"title01":"T-prolymphocytic leukemia: TCL1 or MTCP1 rearrangement is not mandatory to establish diagnosis","title02":"T-prolymphocytic leukemia: <i>TCL1<\/i> or <i>MTCP1<\/i> rearrangement is not mandatory to establish diagnosis","journal":"Leukemia","issue":"Leukemia. 2023 Jul 13. doi: 10.1038\/s41375-023-01956-3. Online ahead of print.","author":"Fang H, Beird HC, Wang SA, Ibrahim AF, Tang Z, Tang G, You MJ, Hu S, Xu J, Li S, Yin CC, El Hussein S, Le N, Futreal PA, Bueso-Ramos C, Thakral B, Kadia TM, Thornton R, Little L, Gumbs C, Song X, Medeiros LJ, Wang W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37443196"},{"title01":"Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo","title02":"Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML <i>RUNX1-RUNX1T1<\/i> fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo","journal":"Leukemia","issue":"Leukemia. 2023 Jul 18. doi: 10.1038\/s41375-023-01950-9. Online ahead of print.","author":"Neldeborg S, Soerensen JF, M\u00f8ller CT, Bill M, Gao Z, Bak RO, Holm K, Sorensen B, Nyegaard M, Luo Y, Hokland P, Stougaard M, Ludvigsen M, Holm CK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37464068"},{"title01":"IgH 3&#8217;RR recombination uncovers a non-germinal center imprint and c-MYC-dependent IgH rearrangement in unmutated chronic lymphocytic leukemia","title02":"IgH 3&#8217;RR recombination uncovers a non-germinal center imprint and c-MYC-dependent IgH rearrangement in unmutated chronic lymphocytic leukemia","journal":"Haematologica","issue":"Haematologica. 2023 Jul 27. doi: 10.3324\/haematol.2023.282897. Online ahead of print.","author":"Al Jamal I, Parquet M, Guiyedi K, Aoufouchi S, Le Guillou M, Rizzo D, Pollet J, Dupont M, Boulin M, Faumont N, Boutouil H, Jardin F, Ruminy P, El Hamel C, Lerat J, Al Hamaoui S, Makdissy N, Feuillard J, Gachard N, Peron S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37496419"},{"title01":"DNAJC10 maintains survival and self-renewal of leukemia stem cells through PERK branch of the unfolded protein response","title02":"DNAJC10 maintains survival and self-renewal of leukemia stem cells through PERK branch of the unfolded protein response","journal":"Haematologica","issue":"Haematologica. 2023 Jul 27. doi: 10.3324\/haematol.2023.282691. Online ahead of print.","author":"Li M, Wu X, Chen M, Hao S, Yu Y, Li X, Zhao E, Xu M, Yu Z, Wang Z, Xu N, Jin C, Yin Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37496439"},{"title01":"Co-stimulatory and immune checkpoint molecules are important in the tumor microenvironment of Hodgkin-like adult T-cell leukemia\/lymphoma","title02":"Co-stimulatory and immune checkpoint molecules are important in the tumor microenvironment of Hodgkin-like adult T-cell leukemia\/lymphoma","journal":"Haematologica","issue":"Haematologica. 2023 Jul 13. doi: 10.3324\/haematol.2023.283163. Online ahead of print.","author":"Takeuchi M, Miyoshi H, Semba Y, Yamada K, Nakashima K, Sato K, Furuta T, Moritsubo M, Ogura Y, Tanaka K, Imamoto T, Arakawa F, Kohno K, Ohshima K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37439334"},{"title01":"Pro-inflammatory cells sustain leukemic clonal expansion in T-cell large granular lymphocyte leukemia","title02":"Pro-inflammatory cells sustain leukemic clonal expansion in T-cell large granular lymphocyte leukemia","journal":"Haematologica","issue":"Haematologica. 2023 Jul 13. doi: 10.3324\/haematol.2022.282306. Online ahead of print.","author":"Vicenzetto C, Gasparini VR, Barila G, Teramo A, Calabretto G, Rampazzo E, Carraro S, Trimarco V, Trentin L, Facco M, Semenzato G, Zambello R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37439335"},{"title01":"Down syndrome and leukemia: from basic mechanisms to clinical advances","title02":"Down syndrome and leukemia: from basic mechanisms to clinical advances","journal":"Haematologica","issue":"Haematologica. 2023 Jul 13. doi: 10.3324\/haematol.2023.283225. Online ahead of print.","author":"Baruchel A, Bourquin JP, Crispino J, Cuartero S, Hasle H, Hitzler J, Klusmann JH, Izraeli S, Lane AA, Malinge S, Rabin KR, Roberts I, Ryeom S, Tasian SK, Wagenblast E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37439336"},{"title01":"The (near) miracle of therapy in chronic myeloid leukaemia","title02":"The (near) miracle of therapy in chronic myeloid leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 26. doi: 10.1111\/bjh.18956. Online ahead of print.","author":"Radich JP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37495373"},{"title01":"ZBTB16::RARA variant acute promyelocytic leukemia (vAPL) treated with gemtuzumab ozogamicin (GO) with unique pathology and genetic findings","title02":"<i>ZBTB16::RARA<\/i> variant acute promyelocytic leukemia (vAPL) treated with gemtuzumab ozogamicin (GO) with unique pathology and genetic findings","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 26. doi: 10.1111\/bjh.18950. Online ahead of print.","author":"Kassem AM, Keinath MC, Adler JA, Gadde R, Tomlinson BK, Shetty S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37495505"},{"title01":"Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome","title02":"Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 16. doi: 10.1111\/bjh.18982. Online ahead of print.","author":"Pastore F, Gittinger H, Raab S, Tschuri S, Ksienzyk B, Konstandin NP, Schneider S, Rothenberg-Thurley M, Horny HP, Werner M, Sauerland MC, Amler S, G\u00f6rlich D, Berdel WE, W\u00f6rmann B, Braess J, Hiddemann W, Tischer J, Herold T, Metzeler KH, Spiekermann K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37455345"},{"title01":"FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia","title02":"FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 17. doi: 10.1111\/bjh.18971. Online ahead of print.","author":"Peschke JC, Bergmann R, Mehnert M, Gonzalez Soto KE, Loureiro LR, Mitwasi N, Kegler A, Altmann H, Wobus M, M\u00e1th\u00e9 D, Szigeti K, Feldmann A, Bornh\u00e4user M, Bachmann M, Fasslrinner F, Arndt C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37460273"},{"title01":"Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1","title02":"Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting <i>BCR::ABL1<\/i>","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 19. doi: 10.1111\/bjh.18983. Online ahead of print.","author":"Feng H, Fu Y, Cui Z, Zhou M, Zhang L, Gao Z, Ma S, Chen C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37469124"},{"title01":"Targeting STAT5B in T-cell acute lymphoblastic leukemia","title02":"Targeting STAT5B in T-cell acute lymphoblastic leukemia","journal":"Blood","issue":"2023 Jul 20;142(3):215-217.","author":"Veloso A, Cools J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37471110"},{"title01":"Poverty and health equity in childhood leukemia","title02":"Poverty and health equity in childhood leukemia","journal":"Blood","issue":"2023 Jul 20;142(3):211-212.","author":"Gramatges MM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37471111"},{"title01":"Venetoclax with Decitabine as Frontline Treatment for Younger Adults with Newly Diagnosed ELN Adverse-Risk AML","title02":"Venetoclax with Decitabine as Frontline Treatment for Younger Adults with Newly Diagnosed ELN Adverse-Risk AML","journal":"Blood","issue":"Blood. 2023 Jul 21:blood.2023020102. doi: 10.1182\/blood.2023020102. Online ahead of print.","author":"Xie J, Bao X, Xue SL, Shen H, Cen J, Yao L, Pan J, Zhu M, Liu D, Hu X, Wu Q, Zhang J, Dai H, Cao Y, He X, Tang X, Sun AN, Wang Y, Fu J, Qiu H, Yang X, Chen S, Wu D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37478399"},{"title01":"Venetoclax Abrogates the Prognostic Impact of Splicing Factor Gene Mutations in Newly Diagnosed Acute Myeloid Leukemia","title02":"Venetoclax Abrogates the Prognostic Impact of Splicing Factor Gene Mutations in Newly Diagnosed Acute Myeloid Leukemia","journal":"Blood","issue":"Blood. 2023 Jul 13:blood.2023020649. doi: 10.1182\/blood.2023020649. Online ahead of print.","author":"Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce SA, Chien KS, Sasaki K, Kadia TM, Hammond D, Borthakur G, Patel KP, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37441846"},{"title01":"Escape from T-cell targeting immunotherapies in acute myeloid leukemia","title02":"Escape from T-cell targeting immunotherapies in acute myeloid leukemia","journal":"Blood","issue":"Blood. 2023 Jul 19:blood.2023019961. doi: 10.1182\/blood.2023019961. Online ahead of print.","author":"Vadakekolathu J, Rutella S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37467496"},{"title01":"Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)","title02":"Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)","journal":"Leukemia","issue":"Leukemia. 2023 Jul 26. doi: 10.1038\/s41375-023-01977-y. Online ahead of print.","author":"Scheubeck G, Jiang L, Hermine O, Kluin-Nelemans HC, Schmidt C, Unterhalt M, Rosenwald A, Klapper W, Evangelista A, Ladetto M, Jerkeman M, Ferrero S, Dreyling M, Hoster E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37495776"},{"title01":"Co-stimulatory and immune checkpoint molecules are important in the tumor microenvironment of Hodgkin-like adult T-cell leukemia\/lymphoma","title02":"Co-stimulatory and immune checkpoint molecules are important in the tumor microenvironment of Hodgkin-like adult T-cell leukemia\/lymphoma","journal":"Haematologica","issue":"Haematologica. 2023 Jul 13. doi: 10.3324\/haematol.2023.283163. Online ahead of print.","author":"Takeuchi M, Miyoshi H, Semba Y, Yamada K, Nakashima K, Sato K, Furuta T, Moritsubo M, Ogura Y, Tanaka K, Imamoto T, Arakawa F, Kohno K, Ohshima K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37439334"},{"title01":"Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed\/refractory T-cell lymphoma: results from a phase I\/II open-label multicenter study","title02":"Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed\/refractory T-cell lymphoma: results from a phase I\/II open-label multicenter study","journal":"Haematologica","issue":"Haematologica. 2023 Jul 13. doi: 10.3324\/haematol.2022.281875. Online ahead of print.","author":"Iyer SP, Huen A, Ai WZ, Jagadeesh D, Lechowicz MJ, Okada C, Feldman TA, Ghione P, Alderuccio JP, Champion R, Kim SH, Mohrbacher A, Routhu KV, Barde P, Nair AM, Haverkos BM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37439343"},{"title01":"Results from a phase I trial of pembrolizumab plus vorinostat in relapsed\/refractory B-cell non-Hodgkin lymphoma","title02":"Results from a phase I trial of pembrolizumab plus vorinostat in relapsed\/refractory B-cell non-Hodgkin lymphoma","journal":"Haematologica","issue":"Haematologica. 2023 Jul 20. doi: 10.3324\/haematol.2023.283002. Online ahead of print.","author":"Godfrey J, Mei M, Chen L, Song JY, Bedell V, Budde E, Armenian S, Puverel S, Nikolaenko L, Chen R, Daniels S, Kennedy N, Peters L, Rosen ST, Forman SJ, Popplewell LL, Kwak LW, Herrera AF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37470137"},{"title01":"Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma, including those with poor prognostic factors","title02":"Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma, including those with poor prognostic factors","journal":"Haematologica","issue":"Haematologica. 2023 Jul 20. doi: 10.3324\/haematol.2022.282469. Online ahead of print.","author":"Le Gouill S, D\u0142ugosz-Danecka M, Rule S, Zinzani PL, Goy A, Smith SD, Doorduijn JK, Panizo C, Shah BD, Davies AJ, Eek R, Jacobsen E, Kater AP, Robak T, Jain P, Calvo R, Tao L, Wang M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37470152"},{"title01":"Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario","title02":"Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 20. doi: 10.1111\/bjh.18972. Online ahead of print.","author":"Suleman A, Aktar SJ, Ante Z, Liu N, Chan KKW, Cheung MC, Prica A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37474340"},{"title01":"Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO","title02":"Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 23. doi: 10.1111\/bjh.18989. Online ahead of print.","author":"Mart\u00edn Garc\u00eda-Sancho A, Baile M, Rodr\u00edguez G, Dlouhy I, Sancho JM, Jarque I, Gonz\u00e1lez-Barca E, Salar A, Espeso M, Grande C, Bergua J, Montes-Moreno S, Redondo A, Enjuanes A, Campo E, L\u00f3pez-Guillermo A, Caballero D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37485564"},{"title01":"Unexpected MYC::DMD translocation after transformation of follicular lymphoma with IGH::BCL2 and IGH::MYC","title02":"Unexpected <i>MYC::DMD<\/i> translocation after transformation of follicular lymphoma with <i>IGH::BCL2<\/i> and <i>IGH::MYC<\/i>","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 23. doi: 10.1111\/bjh.18994. Online ahead of print.","author":"Carlsen ED, Aarabi M, Swerdlow SH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37485649"},{"title01":"Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas","title02":"Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 24. doi: 10.1111\/bjh.19001. Online ahead of print.","author":"Gao J, Dahiya S, Patel SA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37488074"},{"title01":"Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma","title02":"Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 16. doi: 10.1111\/bjh.18974. Online ahead of print.","author":"Gao F, Liu H, Meng X, Liu J, Wang J, Yu J, Liu X, Liu X, Li L, Qiu L, Qian Z, Zhou S, Gong W, Meng B, Ren X, Golchehre Z, Chavoshzadeh Z, He J, Zhang H, Wang X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37455019"},{"title01":"MYD88L265P Augments Proximal B-Cell Receptor Signaling in Large B-Cell Lymphomas Via an Interaction with DOCK8","title02":"MYD88L265P Augments Proximal B-Cell Receptor Signaling in Large B-Cell Lymphomas Via an Interaction with DOCK8","journal":"Blood","issue":"Blood. 2023 Jul 19:blood.2023019865. doi: 10.1182\/blood.2023019865. Online ahead of print.","author":"Mandato E, Yan Q, Ouyang J, Paczkowska J, Qin Y, Hao Y, Bojarczuk K, Hansen J, Chapuy B, Rodig SJ, Khan SJ, Redd RA, Shipp MA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37467575"},{"title01":"Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future","title02":"Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future","journal":"J Clin Oncol","issue":"J Clin Oncol. 2023 Jul 20:JCO2300512. doi: 10.1200\/JCO.23.00512. Online ahead of print.","author":"Holstein SA, Grant SJ, Wildes TM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37471687"},{"title01":"TTK\/MPS1 inhibitor OSU-13 targets the mitotic checkpoint and is a potential therapeutic strategy for myeloma","title02":"TTK\/MPS1 inhibitor OSU-13 targets the mitotic checkpoint and is a potential therapeutic strategy for myeloma","journal":"Haematologica","issue":"Haematologica. 2023 Jul 27. doi: 10.3324\/haematol.2023.282838. Online ahead of print.","author":"Longo LVG, Hughes T, McNeil-Laidley B, Cottini F, Hilinski G, Merritt E, Benson DM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37496433"},{"title01":"PVT1 interacts with polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma","title02":"<i>PVT1<\/i> interacts with polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma","journal":"Haematologica","issue":"Haematologica. 2023 Jul 27. doi: 10.3324\/haematol.2023.282965. Online ahead of print.","author":"Nylund P, Garrido-Zabala B, P\u00e1rraga AA, Vasquez L, Pyl PT, Harinck GM, Ma A, Jin J, \u00d6berg F, Kalushkova A, Wiklund HJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37496441"},{"title01":"Elotuzumab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials","title02":"Elotuzumab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials","journal":"Haematologica","issue":"Haematologica. 2023 Jul 13. doi: 10.3324\/haematol.2023.283251. Online ahead of print.","author":"Gentile M, Vigna E, Palmieri S, Galli M, Derudas D, Mina R, Pepa RD, Zambello R, Martino EA, Bruzzese A, Mangiacavalli S, Zamagni E, Califano C, Musso M, Conticello C, Cerchione C, Mele G, Di Renzo N, Offidani M, Tarantini G, Casaluci GM, Rago A, Ria R, Uccello G, Baril\u00e0 G, Palumbo G, Pompa A, Vincelli D, Brunori M, Accardi F, Amico V, Amendola A, Fontana R, Bongarzoni V, Rossini B, Cotzia E, Gozzetti A, Rizzi R, Sgherza N, Ferretti E, Bertuglia G, Nappi D, Petrucci MT, Di Raimondo F, Neri A, Morabito F, Musto P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37439329"},{"title01":"Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma","title02":"Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma","journal":"Haematologica","issue":"Haematologica. 2023 Jul 13. doi: 10.3324\/haematol.2022.282521. Online ahead of print.","author":"Khan AM, Dvorak K, Zhao Q, Bumma N, Cottini F, Devarakonda S, Umyarova E, Sharma N, Benson D, Rosko A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37439332"},{"title01":"Higher cyclophosphamide dose grants optimal stem-cell collection after daratumumab-based induction in multiple myeloma","title02":"Higher cyclophosphamide dose grants optimal stem-cell collection after daratumumab-based induction in multiple myeloma","journal":"Haematologica","issue":"Haematologica. 2023 Jul 13. doi: 10.3324\/haematol.2023.283452. Online ahead of print.","author":"Liberatore C, Perini T, Passeri C, Ferla V, Fioritoni F, Girlando V, Iuliani O, Orsini A, Montanaro G, Farina F, Di Nicola A, Nitti R, Pulini S, Mastaglio S, Santarone S, Coppola M, Marktel S, Accorsi P, Ciceri F, Marcatti M, Di Ianni M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37439346"},{"title01":"Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study","title02":"Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study","journal":"Haematologica","issue":"Haematologica. 2023 Jul 13. doi: 10.3324\/haematol.2023.282905. Online ahead of print.","author":"McCurdy A, Seow H, Pond GP, Gayowsky A, Chakraborty R, Visram A, Kaedbey R, D'Souza A, Mohyuddin GR, Wildes TM, Fonseca R, Mian H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37439357"},{"title01":"DIS3 depletion in multiple myeloma causes extensive perturbation in cell cycle progression and centrosome amplification","title02":"<i>DIS3<\/i> depletion in multiple myeloma causes extensive perturbation in cell cycle progression and centrosome amplification","journal":"Haematologica","issue":"Haematologica. 2023 Jul 13. doi: 10.3324\/haematol.2023.283274. Online ahead of print.","author":"Favasuli VK, Ronchetti D, Silvestris I, Puccio N, Fabbiano G, Traini V, Todoerti K, Erratico S, Ciarrocchi A, Fragliasso V, Giannandrea D, Tumiatti F, Chiaramonte R, Torrente Y, Finelli P, Morelli E, Munshi NC, Bolli N, Neri A, Ta\u00ecana E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37439377"},{"title01":"IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma","title02":"IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma","journal":"Haematologica","issue":"Haematologica. 2023 Jul 13. doi: 10.3324\/haematol.2022.282538. Online ahead of print.","author":"Pisano MD, Sun F, Cheng Y, Parashar D, Zhou V, Jing X, Sompallae R, Abrudan J, Zimmermann MT, Mathison A, Janz S, Pufall MA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37439384"},{"title01":"S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma","title02":"S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma","journal":"Haematologica","issue":"Haematologica. 2023 Jul 20. doi: 10.3324\/haematol.2023.282866. Online ahead of print.","author":"Wang Y, Muylaert C, Wyns A, Vlummens P, De Veirman K, Vanderkerken K, Zaal E, Berkers C, Moreaux J, De Bruyne E, Menu E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37470139"},{"title01":"Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs","title02":"Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs","journal":"Haematologica","issue":"Haematologica. 2023 Jul 20. doi: 10.3324\/haematol.2023.283202. Online ahead of print.","author":"Takamatsu H, Matsuda T, Mizuno S, Takahashi T, Fuchida SI, Hanamura I, Kataoka K, Tsukada N, Matsumoto M, Hangaishi A, Doki N, Uchida N, Sawa M, Maruyama Y, Kurahashi S, Nagafuji K, Harazaki Y, Kako S, Iida S, Ichinohe T, Kanda Y, Atsuta Y, Sunami K; Multiple Myeloma Working Group in the Japanese Society for Transplantation and Cellular Therapy.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37470160"},{"title01":"Haematopoietic stem cell mobilisation followed by high-dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma","title02":"Haematopoietic stem cell mobilisation followed by high-dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 24. doi: 10.1111\/bjh.18990. Online ahead of print.","author":"Asher S, Shah R, Ings S, Horder J, Newrick F, Nesr G, Kesse Adu R, Streetly M, Trompeter S, Lee L, Wisniowski B, Mahmood S, Xu K, Papanikalaou X, McMillan A, Popat R, Yong K, Sive J, Kyriakou C, Rabin N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37488061"},{"title01":"Potential future direction of measurable residual disease evaluation in multiple myeloma","title02":"Potential future direction of measurable residual disease evaluation in multiple myeloma","journal":"Blood","issue":"Blood. 2023 Jul 20:blood.2023020284. doi: 10.1182\/blood.2023020284. Online ahead of print.","author":"Mohty M, Avet-Loiseau H, Harousseau JL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37471603"},{"title01":"Are haematopoietic stem cell transplants stem cell transplants, is there a threshold dose of CD34-positive cells and how many are needed for rapid posttransplant granulocyte recovery?","title02":"Are haematopoietic <i>stem cell<\/i> transplants <i>stem cell<\/i> transplants, is there <i>a threshold dose<\/i> of CD34-positive cells and how many are needed for rapid posttransplant granulocyte recovery?","journal":"Leukemia","issue":"Leukemia. 2023 Jul 20. doi: 10.1038\/s41375-023-01973-2. Online ahead of print.","author":"Chen J, Gale RP, Feng Y, Hu Y, Qi S, Liu X, Zhu H, Gong X, Zhang W, Liu H, Sun Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37474589"},{"title01":"Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)","title02":"Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)","journal":"Leukemia","issue":"Leukemia. 2023 Jul 17. doi: 10.1038\/s41375-023-01938-5. Online ahead of print.","author":"Cesaro S, Mikulska M, Hirsch HH, Styczynski J, Meylan S, Cordonnier C, Navarro D, von Lilienfeld-Toal M, Mehra V, Marchesi F, Besson C, Masculano RC, Beutel G, Einsele H, Maertens J, de la Camara R; ECIL 9; Ljungman P, Pagano L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37460673"},{"title01":"Optimizing transplantation procedures through identification of prognostic factors in second remission for children with acute myeloid leukemia with no prior history of transplant","title02":"Optimizing transplantation procedures through identification of prognostic factors in second remission for children with acute myeloid leukemia with no prior history of transplant","journal":"Haematologica","issue":"Haematologica. 2023 Jul 20. doi: 10.3324\/haematol.2023.283203. Online ahead of print.","author":"Ishida H, Tsujimoto SI, Hasegawa D, Sakaguchi H, Yamamoto S, Yanagimachi M, Koh K, Watanabe A, Hama A, Cho Y, Watanabe K, Noguchi M, Takeuchi M, Takita J, Washio K, Kato K, Koike T, Hashii Y, Tabuchi K, Hino M, Atsuta Y, Okamoto Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37470138"},{"title01":"Patient-reported treatment response in chronic graft-versus-host disease","title02":"Patient-reported treatment response in chronic graft-versus-host disease","journal":"Haematologica","issue":"Haematologica. 2023 Jul 20. doi: 10.3324\/haematol.2023.283524. Online ahead of print.","author":"Greinix HT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37470158"},{"title01":"Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs","title02":"Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs","journal":"Haematologica","issue":"Haematologica. 2023 Jul 20. doi: 10.3324\/haematol.2023.283202. Online ahead of print.","author":"Takamatsu H, Matsuda T, Mizuno S, Takahashi T, Fuchida SI, Hanamura I, Kataoka K, Tsukada N, Matsumoto M, Hangaishi A, Doki N, Uchida N, Sawa M, Maruyama Y, Kurahashi S, Nagafuji K, Harazaki Y, Kako S, Iida S, Ichinohe T, Kanda Y, Atsuta Y, Sunami K; Multiple Myeloma Working Group in the Japanese Society for Transplantation and Cellular Therapy.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37470160"},{"title01":"Haematopoietic stem cell mobilisation followed by high-dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma","title02":"Haematopoietic stem cell mobilisation followed by high-dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 24. doi: 10.1111\/bjh.18990. Online ahead of print.","author":"Asher S, Shah R, Ings S, Horder J, Newrick F, Nesr G, Kesse Adu R, Streetly M, Trompeter S, Lee L, Wisniowski B, Mahmood S, Xu K, Papanikalaou X, McMillan A, Popat R, Yong K, Sive J, Kyriakou C, Rabin N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37488061"},{"title01":"Human leucocyte antigen-matched related haematopoietic stem cell transplantation using low-dose cyclophosphamide, fludarabine and thymoglobulin in children with severe aplastic anaemia","title02":"Human leucocyte antigen-matched related haematopoietic stem cell transplantation using low-dose cyclophosphamide, fludarabine and thymoglobulin in children with severe aplastic anaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 25. doi: 10.1111\/bjh.19004. Online ahead of print.","author":"Alsultan A, Abujoub R, Alsudairy R, Memon S, Jarrar MS, Alafghani S, Aldaama S, Ballourah W, Almanjomi F, Essa MF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37491781"},{"title01":"Novel developments in the prophylaxis and treatment of acute GVHD","title02":"Novel developments in the prophylaxis and treatment of acute GVHD","journal":"Blood","issue":"Blood. 2023 Jul 20:blood.2023020073. doi: 10.1182\/blood.2023020073. Online ahead of print.","author":"Jamy O, Zeiser R, Chen YB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37471585"},{"title01":"Are haematopoietic stem cell transplants stem cell transplants, is there a threshold dose of CD34-positive cells and how many are needed for rapid posttransplant granulocyte recovery?","title02":"Are haematopoietic <i>stem cell<\/i> transplants <i>stem cell<\/i> transplants, is there <i>a threshold dose<\/i> of CD34-positive cells and how many are needed for rapid posttransplant granulocyte recovery?","journal":"Leukemia","issue":"Leukemia. 2023 Jul 20. doi: 10.1038\/s41375-023-01973-2. Online ahead of print.","author":"Chen J, Gale RP, Feng Y, Hu Y, Qi S, Liu X, Zhu H, Gong X, Zhang W, Liu H, Sun Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37474589"},{"title01":"Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)","title02":"Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)","journal":"Leukemia","issue":"Leukemia. 2023 Jul 17. doi: 10.1038\/s41375-023-01938-5. Online ahead of print.","author":"Cesaro S, Mikulska M, Hirsch HH, Styczynski J, Meylan S, Cordonnier C, Navarro D, von Lilienfeld-Toal M, Mehra V, Marchesi F, Besson C, Masculano RC, Beutel G, Einsele H, Maertens J, de la Camara R; ECIL 9; Ljungman P, Pagano L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37460673"},{"title01":"DNAJC10 maintains survival and self-renewal of leukemia stem cells through PERK branch of the unfolded protein response","title02":"DNAJC10 maintains survival and self-renewal of leukemia stem cells through PERK branch of the unfolded protein response","journal":"Haematologica","issue":"Haematologica. 2023 Jul 27. doi: 10.3324\/haematol.2023.282691. Online ahead of print.","author":"Li M, Wu X, Chen M, Hao S, Yu Y, Li X, Zhao E, Xu M, Yu Z, Wang Z, Xu N, Jin C, Yin Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37496439"},{"title01":"Higher cyclophosphamide dose grants optimal stem-cell collection after daratumumab-based induction in multiple myeloma","title02":"Higher cyclophosphamide dose grants optimal stem-cell collection after daratumumab-based induction in multiple myeloma","journal":"Haematologica","issue":"Haematologica. 2023 Jul 13. doi: 10.3324\/haematol.2023.283452. Online ahead of print.","author":"Liberatore C, Perini T, Passeri C, Ferla V, Fioritoni F, Girlando V, Iuliani O, Orsini A, Montanaro G, Farina F, Di Nicola A, Nitti R, Pulini S, Mastaglio S, Santarone S, Coppola M, Marktel S, Accorsi P, Ciceri F, Marcatti M, Di Ianni M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37439346"},{"title01":"Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs","title02":"Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs","journal":"Haematologica","issue":"Haematologica. 2023 Jul 20. doi: 10.3324\/haematol.2023.283202. Online ahead of print.","author":"Takamatsu H, Matsuda T, Mizuno S, Takahashi T, Fuchida SI, Hanamura I, Kataoka K, Tsukada N, Matsumoto M, Hangaishi A, Doki N, Uchida N, Sawa M, Maruyama Y, Kurahashi S, Nagafuji K, Harazaki Y, Kako S, Iida S, Ichinohe T, Kanda Y, Atsuta Y, Sunami K; Multiple Myeloma Working Group in the Japanese Society for Transplantation and Cellular Therapy.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37470160"},{"title01":"Haematopoietic stem cell mobilisation followed by high-dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma","title02":"Haematopoietic stem cell mobilisation followed by high-dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 24. doi: 10.1111\/bjh.18990. Online ahead of print.","author":"Asher S, Shah R, Ings S, Horder J, Newrick F, Nesr G, Kesse Adu R, Streetly M, Trompeter S, Lee L, Wisniowski B, Mahmood S, Xu K, Papanikalaou X, McMillan A, Popat R, Yong K, Sive J, Kyriakou C, Rabin N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37488061"},{"title01":"Human leucocyte antigen-matched related haematopoietic stem cell transplantation using low-dose cyclophosphamide, fludarabine and thymoglobulin in children with severe aplastic anaemia","title02":"Human leucocyte antigen-matched related haematopoietic stem cell transplantation using low-dose cyclophosphamide, fludarabine and thymoglobulin in children with severe aplastic anaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 25. doi: 10.1111\/bjh.19004. Online ahead of print.","author":"Alsultan A, Abujoub R, Alsudairy R, Memon S, Jarrar MS, Alafghani S, Aldaama S, Ballourah W, Almanjomi F, Essa MF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37491781"},{"title01":"Outcomes of Hematopoietic Stem Cell Gene Therapy for Wiskott-Aldrich Syndrome","title02":"Outcomes of Hematopoietic Stem Cell Gene Therapy for Wiskott-Aldrich Syndrome","journal":"Blood","issue":"Blood. 2023 Jul 21:blood.2022019117. doi: 10.1182\/blood.2022019117. Online ahead of print.","author":"Labrosse R, Chu J, Armant M, Everett JK, Pellin D, Kareddy N, Frelinger AL, Henderson LA, O'Connell AE, Biswas A, Coenen-van der Spek J, Miggelbrink AM, Fiorini C, Adhikari H, Berry CC, Cantu VA, Fong J, Jaroslavsky JR, Karadeniz DF, Li QZ, Reddy S, Roche AM, Zhu C, Whangbo JS, Dansereau C, Mackinnon BL, Morris E, Koo SM, London WB, Baris S, Ozen A, Karakoc-Aydiner E, Despotovic JM, Forbes Satter LR, Saitoh A, Aizawa Y, King A, Nguyen MAT, Vu VDU, Snapper SB, Galy A, Notarangelo LD, Bushman FD, Williams DA, Pai SY.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37478401"},{"title01":"Long term survivors in severe aplastic anemia: standard mortality rates now comparable to controls?","title02":"Long term survivors in severe aplastic anemia: standard mortality rates now comparable to controls?","journal":"Haematologica","issue":"Haematologica. 2023 Jul 13. doi: 10.3324\/haematol.2023.283523. Online ahead of print.","author":"Bacigalupo A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37439355"},{"title01":"A novel promoter of endothelial dysfunction in African Americans: Relevance to sickle cell anaemia","title02":"A novel promoter of endothelial dysfunction in African Americans: Relevance to sickle cell anaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 23. doi: 10.1111\/bjh.18993. Online ahead of print.","author":"Hebbel RP, Milbauer L, Wei P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37485546"},{"title01":"Human leucocyte antigen-matched related haematopoietic stem cell transplantation using low-dose cyclophosphamide, fludarabine and thymoglobulin in children with severe aplastic anaemia","title02":"Human leucocyte antigen-matched related haematopoietic stem cell transplantation using low-dose cyclophosphamide, fludarabine and thymoglobulin in children with severe aplastic anaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 25. doi: 10.1111\/bjh.19004. Online ahead of print.","author":"Alsultan A, Abujoub R, Alsudairy R, Memon S, Jarrar MS, Alafghani S, Aldaama S, Ballourah W, Almanjomi F, Essa MF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37491781"},{"title01":"Real-world evidence of incidence and outcomes of aplastic anaemia following administration of immune checkpoint inhibitors","title02":"Real-world evidence of incidence and outcomes of aplastic anaemia following administration of immune checkpoint inhibitors","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 16. doi: 10.1111\/bjh.18985. Online ahead of print.","author":"Dasari S, Tse W, Wang J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37455367"},{"title01":"Erythropoiesis-hepcidin-iron axis in patients with X-linked sideroblastic anaemia: An explorative biomarker study","title02":"Erythropoiesis-hepcidin-iron axis in patients with X-linked sideroblastic anaemia: An explorative biomarker study","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 19. doi: 10.1111\/bjh.18986. Online ahead of print.","author":"Hoving V, Nijssen LE, Donker AE, Roelofs R, Schols SEM, Swinkels DW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37469032"},{"title01":"Single cell genomics in acquired bone marrow failure syndromes","title02":"Single cell genomics in acquired bone marrow failure syndromes","journal":"Blood","issue":"Blood. 2023 Jul 21:blood.2022018581. doi: 10.1182\/blood.2022018581. Online ahead of print.","author":"Wu Z, Young NS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37478398"},{"title01":"Obesity is associated with poor outcomes of corticosteroid treatment in patients with primary immune thrombocytopenia","title02":"Obesity is associated with poor outcomes of corticosteroid treatment in patients with primary immune thrombocytopenia","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 24. doi: 10.1111\/bjh.18997. Online ahead of print.","author":"Zhang X, Liu Q, Liu A, Leng S, Wang X, Zhao R, Sheng Z, Feng Q, Yang X, Wang S, Hou M, Peng J, Feng G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37488467"},{"title01":"Platelet count threshold for hemorrhage in patients with immune thrombocytopenia treated with antiplatelet agents","title02":"Platelet count threshold for hemorrhage in patients with immune thrombocytopenia treated with antiplatelet agents","journal":"Blood","issue":"Blood. 2023 Jul 21:blood.2023020311. doi: 10.1182\/blood.2023020311. Online ahead of print.","author":"Ollier N, Piel-Julian ML, Mahevas M, Viallard JF, Comont T, Cheze S, Audia S, Ebbo M, Terriou L, Lega JC, Jeandel PY, Bonnotte B, Michel M, Lapeyre-Mestre M, Godeau B, Moulis G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37478400"},{"title01":"Prognosis of IGLV3-21(R110) chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis","title02":"Prognosis of IGLV3-21(R110) chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis","journal":"Leukemia","issue":"Leukemia. 2023 Jul 21. doi: 10.1038\/s41375-023-01975-0. Online ahead of print.","author":"Hengeveld PJ, Veelken H, van Bergen CAM, Quinten E, Vervoordeldonk MYL, Ismailzada W, Barendse RS, Dubois JMN, van Oers MHJ, Geisler CH, Kater AP, Westerweel PE, Langerak AW, Levin MD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37479761"},{"title01":"Genetic and chemical targeting of the ATPase complex TIP48 and 49 impairs acute myeloid leukemia","title02":"Genetic and chemical targeting of the ATPase complex TIP48 and 49 impairs acute myeloid leukemia","journal":"Leukemia","issue":"Leukemia. 2023 Jul 25. doi: 10.1038\/s41375-023-01971-4. Online ahead of print.","author":"Hattori A, Takamatsu-Ichihara E, Yamamoto Y, Fujita S, Yamagata K, Katsumoto T, Machida Y, Shinohara H, Murakami R, Kitabayashi I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37491463"},{"title01":"Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells","title02":"Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells","journal":"Leukemia","issue":"Leukemia. 2023 Jul 26. doi: 10.1038\/s41375-023-01972-3. Online ahead of print.","author":"Palau A, Segerberg F, Lidschreiber M, Lidschreiber K, Naughton AJ, Needhamsen M, Jung LA, Jagodic M, Cramer P, Lehmann S, Carlsten M, Lennartsson A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37495775"},{"title01":"Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)","title02":"Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)","journal":"Leukemia","issue":"Leukemia. 2023 Jul 17. doi: 10.1038\/s41375-023-01938-5. Online ahead of print.","author":"Cesaro S, Mikulska M, Hirsch HH, Styczynski J, Meylan S, Cordonnier C, Navarro D, von Lilienfeld-Toal M, Mehra V, Marchesi F, Besson C, Masculano RC, Beutel G, Einsele H, Maertens J, de la Camara R; ECIL 9; Ljungman P, Pagano L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37460673"},{"title01":"Autonomous B-cell receptor signaling and genetic aberrations in chronic lymphocytic leukemia-phenotype monoclonal B lymphocytosis in siblings of patients with chronic lymphocytic leukemia","title02":"Autonomous B-cell receptor signaling and genetic aberrations in chronic lymphocytic leukemia-phenotype monoclonal B lymphocytosis in siblings of patients with chronic lymphocytic leukemia","journal":"Haematologica","issue":"Haematologica. 2023 Jul 13. doi: 10.3324\/haematol.2022.282542. Online ahead of print.","author":"Quinten E, Sep\u00falveda-Y\u00e1\u00f1ez JH, Koning MT, Eken JA, Pfeifer D, Nteleah V, De Groen RAL, Saravia DA, Knijnenburg J, Stuivenberg-Bleijswijk HE, Pantic M, Agathangelidis A, Keppler-Hafkemeyer A, Van Bergen CAM, Uribe-Paredes R, Stamatopoulos K, Vermaat JSP, Zirlik K, Navarrete MA, Jumaa H, Veelken H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37439337"},{"title01":"Efficacy and feasibility of pharmacoscopy-guided treatment for acute myeloid leukemia patients who have exhausted all registered therapeutic options","title02":"Efficacy and feasibility of pharmacoscopy-guided treatment for acute myeloid leukemia patients who have exhausted all registered therapeutic options","journal":"Haematologica","issue":"Haematologica. 2023 Jul 13. doi: 10.3324\/haematol.2023.283224. Online ahead of print.","author":"Schmid JA, Festl Y, Severin Y, Bacher U, Kronig MN, Snijder B, Pabst T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37439341"},{"title01":"Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I\/II study","title02":"Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I\/II study","journal":"Haematologica","issue":"Haematologica. 2023 Jul 13. doi: 10.3324\/haematol.2022.281944. Online ahead of print.","author":"Cortes JE, Lipton JH, Kota V, Castagnetti F, Assouline S, Br\u00fcmmendorf TH, Leip E, Viqueira A, Gambacorti-Passerini C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37439348"},{"title01":"Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia","title02":"Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia","journal":"Haematologica","issue":"Haematologica. 2023 Jul 13. doi: 10.3324\/haematol.2023.282760. Online ahead of print.","author":"Chen Z, Cretenet G, Carnazzo V, Simon-Molas H, Kater AP, Windt GJWV, Eldering E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37439352"},{"title01":"Optimizing transplantation procedures through identification of prognostic factors in second remission for children with acute myeloid leukemia with no prior history of transplant","title02":"Optimizing transplantation procedures through identification of prognostic factors in second remission for children with acute myeloid leukemia with no prior history of transplant","journal":"Haematologica","issue":"Haematologica. 2023 Jul 20. doi: 10.3324\/haematol.2023.283203. Online ahead of print.","author":"Ishida H, Tsujimoto SI, Hasegawa D, Sakaguchi H, Yamamoto S, Yanagimachi M, Koh K, Watanabe A, Hama A, Cho Y, Watanabe K, Noguchi M, Takeuchi M, Takita J, Washio K, Kato K, Koike T, Hashii Y, Tabuchi K, Hino M, Atsuta Y, Okamoto Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37470138"},{"title01":"Secondary acute myeloid leukemia: time to turn the page","title02":"Secondary acute myeloid leukemia: time to turn the page","journal":"Haematologica","issue":"Haematologica. 2023 Jul 20. doi: 10.3324\/haematol.2023.283468. Online ahead of print.","author":"R\u00e9cher C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37470142"},{"title01":"Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed\/refractory acute myeloid leukemia","title02":"Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed\/refractory acute myeloid leukemia","journal":"Haematologica","issue":"Haematologica. 2023 Jul 20. doi: 10.3324\/haematol.2023.282912. Online ahead of print.","author":"Shahswar R, Beutel G, Gabdoulline R, Schwarzer A, Kloos A, Koenecke C, Stadler M, Gohring G, Behrens YL, Li Z, Dallmann LK, Klement P, Albert C, Wichmann M, Alwie Y, Benner A, Saadati M, Ganser A, Thol F, Heuser M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37470150"},{"title01":"Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed\/refractory T-cell acute lymphoblastic leukemia","title02":"Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed\/refractory T-cell acute lymphoblastic leukemia","journal":"Haematologica","issue":"Haematologica. 2023 Jul 20. doi: 10.3324\/haematol.2023.283566. Online ahead of print.","author":"Aldoss I, Tizro P, Bedi D, Mangan JK, Clark MC, Spencer D, Song JY, Cherian S, Pillai R, Kim Y, Mahajan N, Gendzekhadze K, James M, Jacobs K, Davidson-Moncada J, Forman SJ, Wang HY, Afkhami M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37470155"},{"title01":"Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha","title02":"Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 22. doi: 10.1111\/bjh.18984. Online ahead of print.","author":"Irani YD, Hughes A, Kok CH, Clarson J, Yeung DT, Ross DM, Branford S, Hughes TP, Yong ASM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37482935"},{"title01":"Functional characterization and response to FLT3 inhibitors in acute myeloid leukaemia with a non-canonical FLT3 mutation: A proof of concept","title02":"Functional characterization and response to FLT3 inhibitors in acute myeloid leukaemia with a non-canonical FLT3 mutation: A proof of concept","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 23. doi: 10.1111\/bjh.18991. Online ahead of print.","author":"Travaglini S, Gurnari C, Antonelli S, Marchesi F, De Angelis G, Ottone T, Divona M, Cristiano A, Hajrullaj H, Mengarelli A, Voso MT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37485586"},{"title01":"Focal adhesion kinase activation by calcium-dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness","title02":"Focal adhesion kinase activation by calcium-dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness","journal":"Br J Haematol","issue":"Br J Haematol. 2023 Jul 26. doi: 10.1111\/bjh.18996. Online ahead of print.","author":"Severin F, Mouawad N, Ruggeri E, Visentin A, Martinello L, Pagnin E, Trimarco V, Pravato S, Angotzi F, Facco M, Trentin L, Frezzato F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37495265"}]